PAHC 10-Q Quarterly Report Dec. 31, 2014 | Alphaminr
PHIBRO ANIMAL HEALTH CORP
ALPHAMINR

PAHC 10-Q Quarter ended Dec. 31, 2014

Balance Sheet
Cash Flow
Income Statement
Debt
PHIBRO ANIMAL HEALTH CORP
10-Ks and 10-Qs
10-Q
Quarter ended Sept. 30, 2025
10-K
Fiscal year ended June 30, 2025
10-Q
Quarter ended March 31, 2025
10-Q
Quarter ended Dec. 31, 2024
10-Q
Quarter ended Sept. 30, 2024
10-K
Fiscal year ended June 30, 2024
10-Q
Quarter ended March 31, 2024
10-Q
Quarter ended Dec. 31, 2023
10-Q
Quarter ended Sept. 30, 2023
10-K
Fiscal year ended June 30, 2023
10-Q
Quarter ended March 31, 2023
10-Q
Quarter ended Dec. 31, 2022
10-Q
Quarter ended Sept. 30, 2022
10-K
Fiscal year ended June 30, 2022
10-Q
Quarter ended March 31, 2022
10-Q
Quarter ended Dec. 31, 2021
10-Q
Quarter ended Sept. 30, 2021
10-K
Fiscal year ended June 30, 2021
10-Q
Quarter ended March 31, 2021
10-Q
Quarter ended Dec. 31, 2020
10-Q
Quarter ended Sept. 30, 2020
10-K
Fiscal year ended June 30, 2020
10-Q
Quarter ended March 31, 2020
10-Q
Quarter ended Dec. 31, 2019
10-Q
Quarter ended Sept. 30, 2019
10-K
Fiscal year ended June 30, 2019
10-Q
Quarter ended March 31, 2019
10-Q
Quarter ended Dec. 31, 2018
10-Q
Quarter ended Sept. 30, 2018
10-K
Fiscal year ended June 30, 2018
10-Q
Quarter ended March 31, 2018
10-Q
Quarter ended Dec. 31, 2017
10-Q
Quarter ended Sept. 30, 2017
10-K
Fiscal year ended June 30, 2017
10-Q
Quarter ended March 31, 2017
10-Q
Quarter ended Dec. 31, 2016
10-Q
Quarter ended Sept. 30, 2016
10-K
Fiscal year ended June 30, 2016
10-Q
Quarter ended March 31, 2016
10-Q
Quarter ended Dec. 31, 2015
10-Q
Quarter ended Sept. 30, 2015
10-K
Fiscal year ended June 30, 2015
10-Q
Quarter ended March 31, 2015
10-Q
Quarter ended Dec. 31, 2014
10-Q
Quarter ended Sept. 30, 2014
10-K
Fiscal year ended June 30, 2014
10-Q
Quarter ended March 31, 2014
PROXIES
DEF 14A
Filed on Nov. 4, 2025
DEF 14A
Filed on Nov. 5, 2024
DEF 14A
Filed on Sept. 20, 2024
DEF 14A
Filed on Nov. 6, 2023
DEF 14A
Filed on Sept. 15, 2023
DEF 14A
Filed on Nov. 7, 2022
DEF 14A
Filed on Sept. 16, 2022
DEF 14A
Filed on Sept. 17, 2021
DEF 14A
Filed on Sept. 18, 2020
DEF 14A
Filed on Sept. 20, 2019
DEF 14A
Filed on Sept. 21, 2018
DEF 14A
Filed on Sept. 22, 2017
DEF 14A
Filed on Sept. 23, 2016
DEF 14A
Filed on Sept. 24, 2015
DEF 14A
Filed on Sept. 24, 2014
10-Q 1 t1500255-10q.htm FORM 10-Q t1500255-10q - none - 5.4615461s
​
​
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
​
FORM 10-Q
​
(Mark One)
☒
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
​
For the quarterly period ended December 31, 2014
OR
☐
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
​
For the transition period from_____ to_____
Commission File Number: 001-36410
​
Phibro Animal Health Corporation
(Exact name of registrant as specified in its charter) ​
​
​
Delaware
​ ​
13-1840497
​
​
(State or other jurisdiction of
incorporation or organization)
​ ​
(I.R.S. Employer
Identification No.)
​
​
Glenpointe Centre East, 3 rd Floor
300 Frank W. Burr Boulevard, Suite 21
Teaneck, New Jersey
(Address of Principal Executive Offices)
​ ​
07666-6712
(Zip Code)
​
(201) 329-7300
(Registrant’s telephone number, including area code)
​
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files.) Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of  “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.
​ Large accelerated filer ​ ​ ☐ ​ ​ ​ ​ ​ Accelerated filer ​ ​ ☐ ​
​ Non-accelerated filer ​ ​ ☒ ​ ​ ​ ​ ​ Smaller reporting company ​ ​ ☐ ​
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes ☐ No ☒
As of February 3, 2015, there were 17,478,373 shares of the registrant’s Class A common stock, par value $0.0001 per share, and 21,512,275 shares of the registrant’s Class B common stock, par value $0.0001 per share, outstanding.
​
​
PHIBRO ANIMAL HEALTH CORPORATION
TABLE OF CONTENTS
​ ​ ​
Page
​
PART I—
FINANCIAL INFORMATION
​
​ ​ ​ ​ ​ ​ ​
Item 1.
Financial Statements (unaudited)
​
​ ​ ​ ​ ​ ​ ​
​ ​ ​ ​ 3 ​ ​
​ ​ ​ ​ 4 ​ ​
​ ​ ​ ​ 5 ​ ​
​ ​ ​ ​ 6 ​ ​
​ ​ ​ ​ 7 ​ ​
​ ​ ​ ​ 17 ​ ​
​ ​ ​ ​ 28 ​ ​
​ ​ ​ ​ 28 ​ ​
PART II—OTHER INFORMATION ​ ​
​ ​ ​ ​ 29 ​ ​
​ ​ ​ ​ 29 ​ ​
​ ​ ​ ​ 29 ​ ​
​ ​ ​ ​ 29 ​ ​
​ ​ ​ ​ 29 ​ ​
​ ​ ​ ​ 29 ​ ​
​ ​ ​ ​ 29 ​ ​
​ ​ ​ ​ 30 ​ ​
2
PART I—FINANCIAL INFORMATION
Item 1.
Financial Statements
​
PHIBRO ANIMAL HEALTH CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
​ ​ ​
Three Months
​ ​
Six Months
​ ​ ​
For the Periods Ended December 31
​ ​
2014
​ ​
2013
​ ​
2014
​ ​
2013
​ ​ ​
​ ​ ​
(unaudited)
(in thousands, except per share amounts)
​ ​ ​ ​ ​ ​ ​
Net sales
​ ​ ​ $ 188,688 ​ ​ ​ ​ $ 172,742 ​ ​ ​ ​ $ 376,146 ​ ​ ​ ​ $ 334,970 ​ ​ ​ ​
Cost of goods sold
​ ​ ​ ​ 132,603 ​ ​ ​ ​ ​ 121,586 ​ ​ ​ ​ ​ 259,732 ​ ​ ​ ​ ​ 234,302 ​ ​ ​ ​
Gross profit
​ ​ ​ ​ 56,085 ​ ​ ​ ​ ​ 51,156 ​ ​ ​ ​ ​ 116,414 ​ ​ ​ ​ ​ 100,668 ​ ​ ​ ​
Selling, general and administrative expenses
​ ​ ​ ​ 36,298 ​ ​ ​ ​ ​ 34,138 ​ ​ ​ ​ ​ 71,522 ​ ​ ​ ​ ​ 67,253 ​ ​ ​ ​
Operating income
​ ​ ​ ​ 19,787 ​ ​ ​ ​ ​ 17,018 ​ ​ ​ ​ ​ 44,892 ​ ​ ​ ​ ​ 33,415 ​ ​ ​ ​
Interest expense
​ ​ ​ ​ 3,550 ​ ​ ​ ​ ​ 7,783 ​ ​ ​ ​ ​ 7,102 ​ ​ ​ ​ ​ 15,557 ​ ​ ​ ​
Interest expense, stockholders
​ ​ ​ ​ — ​ ​ ​ ​ ​ 1,004 ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ 2,009 ​ ​ ​ ​
Interest (income)
​ ​ ​ ​ (35 ) ​ ​ ​ ​ ​ (68 ) ​ ​ ​ ​ ​ (97 ) ​ ​ ​ ​ ​ (112 ) ​ ​ ​ ​
Foreign currency (gains) losses, net
​ ​ ​ ​ (1,018 ) ​ ​ ​ ​ ​ 1,165 ​ ​ ​ ​ ​ (2,222 ) ​ ​ ​ ​ ​ 1,813 ​ ​ ​ ​
Income before income taxes
​ ​ ​ ​ 17,290 ​ ​ ​ ​ ​ 7,134 ​ ​ ​ ​ ​ 40,109 ​ ​ ​ ​ ​ 14,148 ​ ​ ​ ​
Provision for income taxes
​ ​ ​ ​ 1,885 ​ ​ ​ ​ ​ 4,832 ​ ​ ​ ​ ​ 4,223 ​ ​ ​ ​ ​ 6,003 ​ ​ ​ ​
Net income
​ ​ ​ $ 15,405 ​ ​ ​ ​ $ 2,302 ​ ​ ​ ​ $ 35,886 ​ ​ ​ ​ $ 8,145 ​ ​ ​ ​
Net income per share: ​ ​ ​ ​ ​ ​ ​
basic
​ ​ ​ $ 0.40 ​ ​ ​ ​ $ 0.08 ​ ​ ​ ​ $ 0.92 ​ ​ ​ ​ $ 0.27 ​ ​ ​ ​
diluted
​ ​ ​ $ 0.39 ​ ​ ​ ​ $ 0.08 ​ ​ ​ ​ $ 0.90 ​ ​ ​ ​ $ 0.27 ​ ​ ​ ​
Weighted average common shares outstanding: ​ ​ ​ ​ ​ ​ ​
basic
​ ​ ​ ​ 38,957 ​ ​ ​ ​ ​ 30,458 ​ ​ ​ ​ ​ 38,928 ​ ​ ​ ​ ​ 30,458 ​ ​ ​ ​
diluted
​ ​ ​ ​ 39,813 ​ ​ ​ ​ ​ 30,458 ​ ​ ​ ​ ​ 39,690 ​ ​ ​ ​ ​ 30,458 ​ ​ ​ ​
Dividends per share
​ ​ ​ $ 0.10 ​ ​ ​ ​ $ — ​ ​ ​ ​ $ 0.20 ​ ​ ​ ​ $ — ​ ​ ​ ​
The accompanying notes are an integral part of these consolidated financial statements
3
PHIBRO ANIMAL HEALTH CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
​ ​ ​
Three Months
​ ​
Six Months
​
For the Periods Ended December 31
​ ​
2014
​ ​
2013
​ ​
2014
​ ​
2013
​
​ ​ ​
(unaudited)
(in thousands)
​
Net income
​ ​ ​ $ 15,405 ​ ​ ​ ​ $ 2,302 ​ ​ ​ ​ $ 35,886 ​ ​ ​ ​ $ 8,145 ​ ​
Fair value of derivative instruments
​ ​ ​ ​ (294 ) ​ ​ ​ ​ ​ (235 ) ​ ​ ​ ​ ​ (723 ) ​ ​ ​ ​ ​ 137 ​ ​
Foreign currency translation adjustment
​ ​ ​ ​ (7,358 ) ​ ​ ​ ​ ​ (3,003 ) ​ ​ ​ ​ ​ (17,338 ) ​ ​ ​ ​ ​ (3,135 ) ​ ​
Unrecognized net pension gains (losses)
​ ​ ​ ​ 417 ​ ​ ​ ​ ​ 226 ​ ​ ​ ​ ​ 702 ​ ​ ​ ​ ​ 429 ​ ​
(Provision) benefit for income taxes
​ ​ ​ ​ — ​ ​ ​ ​ ​ 3 ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ (221 ) ​ ​
Other comprehensive income (loss)
​ ​ ​ ​ (7,235 ) ​ ​ ​ ​ ​ (3,009 ) ​ ​ ​ ​ ​ (17,359 ) ​ ​ ​ ​ ​ (2,790 ) ​ ​
Comprehensive income (loss)
​ ​ ​ $ 8,170 ​ ​ ​ ​ $ (707 ) ​ ​ ​ ​ $ 18,527 ​ ​ ​ ​ $ 5,355 ​ ​
​
The accompanying notes are an integral part of these consolidated financial statements
4
PHIBRO ANIMAL HEALTH CORPORATION AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
As of
​ ​
December 31,
2014
​ ​
June 30,
2014
​
​ ​ ​
(unaudited)
(in thousands, except share and
per share amounts)
​
ASSETS ​ ​ ​
Cash and cash equivalents
​ ​ ​ $ 20,689 ​ ​ ​ ​ $ 11,821 ​ ​
Accounts receivable, net
​ ​ ​ ​ 114,264 ​ ​ ​ ​ ​ 113,858 ​ ​
Inventories, net
​ ​ ​ ​ 144,858 ​ ​ ​ ​ ​ 143,184 ​ ​
Prepaid expenses and other current assets
​ ​ ​ ​ 26,932 ​ ​ ​ ​ ​ 30,426 ​ ​
Total current assets
​ ​ ​ ​ 306,743 ​ ​ ​ ​ ​ 299,289 ​ ​
Property, plant and equipment, net
​ ​ ​ ​ 102,616 ​ ​ ​ ​ ​ 109,159 ​ ​
Intangibles, net
​ ​ ​ ​ 27,638 ​ ​ ​ ​ ​ 29,803 ​ ​
Other assets
​ ​ ​ ​ 30,680 ​ ​ ​ ​ ​ 34,072 ​ ​
Total assets
​ ​ ​ $ 467,677 ​ ​ ​ ​ $ 472,323 ​ ​
LIABILITIES AND STOCKHOLDERS’ EQUITY ​ ​ ​
Current portion of long-term debt
​ ​ ​ $ 2,828 ​ ​ ​ ​ $ 2,969 ​ ​
Accounts payable
​ ​ ​ ​ 56,762 ​ ​ ​ ​ ​ 59,608 ​ ​
Accrued expenses and other current liabilities
​ ​ ​ ​ 41,788 ​ ​ ​ ​ ​ 49,861 ​ ​
Total current liabilities
​ ​ ​ ​ 101,378 ​ ​ ​ ​ ​ 112,438 ​ ​
Long-term debt
​ ​ ​ ​ 285,113 ​ ​ ​ ​ ​ 286,422 ​ ​
Other liabilities
​ ​ ​ ​ 55,143 ​ ​ ​ ​ ​ 58,314 ​ ​
Total liabilities
​ ​ ​ ​ 441,634 ​ ​ ​ ​ ​ 457,174 ​ ​
Commitments and contingencies (Note 10) ​ ​ ​
Common stock, par value $0.0001; 300,000,000 Class A shares authorized, 17,456,373 and 17,442,953 shares issued and outstanding at December 31, 2014 and June 30, 2014, respectively; 30,000,000 Class B shares authorized, 21,512,275 and 21,348,600 shares issued and outstanding at December 31, 2014 and June 30, 2014, respectively
​ ​ ​ ​ 4 ​ ​ ​ ​ ​ 4 ​ ​
Preferred stock, par value $0.0001; 16,000,000 shares authorized, no shares issued and outstanding
​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​
Paid-in capital
​ ​ ​ ​ 124,820 ​ ​ ​ ​ ​ 132,453 ​ ​
Accumulated deficit
​ ​ ​ ​ (61,362 ) ​ ​ ​ ​ ​ (97,248 ) ​ ​
Accumulated other comprehensive income (loss)
​ ​ ​ ​ (37,419 ) ​ ​ ​ ​ ​ (20,060 ) ​ ​
Total stockholders’ equity
​ ​ ​ ​ 26,043 ​ ​ ​ ​ ​ 15,149 ​ ​
Total liabilities and stockholders’ equity
​ ​ ​ $ 467,677 ​ ​ ​ ​ $ 472,323 ​ ​
​
The accompanying notes are an integral part of these consolidated financial statements
5
PHIBRO ANIMAL HEALTH CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
​ ​ ​
Six Months
​
For the Periods Ended December 31
​ ​
2014
​ ​
2013
​
​ ​ ​
(unaudited)
(in thousands)
​
OPERATING ACTIVITIES ​ ​ ​
Net income
​ ​ ​ $ 35,886 ​ ​ ​ ​ $ 8,145 ​ ​
Adjustments to reconcile net income to net cash provided (used) by operating activities:
​ ​ ​
Depreciation and amortization
​ ​ ​ ​ 10,594 ​ ​ ​ ​ ​ 10,493 ​ ​
Amortization of deferred financing costs and debt discount
​ ​ ​ ​ 483 ​ ​ ​ ​ ​ 786 ​ ​
Deferred income taxes
​ ​ ​ ​ (2,530 ) ​ ​ ​ ​ ​ (108 ) ​ ​
Foreign currency (gains) losses, net
​ ​ ​ ​ (1,046 ) ​ ​ ​ ​ ​ 1,266 ​ ​
Other
​ ​ ​ ​ (21 ) ​ ​ ​ ​ ​ (191 ) ​ ​
Changes in operating assets and liabilities: ​ ​ ​
Accounts receivable, net
​ ​ ​ ​ (3,440 ) ​ ​ ​ ​ ​ (4,380 ) ​ ​
Inventories, net
​ ​ ​ ​ (9,281 ) ​ ​ ​ ​ ​ (2,471 ) ​ ​
Prepaid expenses and other current assets
​ ​ ​ ​ 4,557 ​ ​ ​ ​ ​ (424 ) ​ ​
Other assets
​ ​ ​ ​ 101 ​ ​ ​ ​ ​ (157 ) ​ ​
Accounts payable
​ ​ ​ ​ (1,999 ) ​ ​ ​ ​ ​ 2,459 ​ ​
Accrued interest
​ ​ ​ ​ 54 ​ ​ ​ ​ ​ 20 ​ ​
Accrued expenses and other liabilities
​ ​ ​ ​ (7,595 ) ​ ​ ​ ​ ​ 958 ​ ​
Net cash provided (used) by operating activities
​ ​ ​ ​ 25,763 ​ ​ ​ ​ ​ 16,396 ​ ​
INVESTING ACTIVITIES ​ ​ ​
Capital expenditures
​ ​ ​ ​ (7,728 ) ​ ​ ​ ​ ​ (9,765 ) ​ ​
Other
​ ​ ​ ​ 809 ​ ​ ​ ​ ​ 9 ​ ​
Net cash provided (used) by investing activities
​ ​ ​ ​ (6,919 ) ​ ​ ​ ​ ​ (9,756 ) ​ ​
FINANCING ACTIVITIES ​ ​ ​
Borrowings under the domestic senior and revolving credit facility
​ ​ ​ ​ — ​ ​ ​ ​ ​ 75,500 ​ ​
Repayments of the domestic senior and revolving credit facility
​ ​ ​ ​ — ​ ​ ​ ​ ​ (77,500 ) ​ ​
Payments of long-term debt, capital leases and other
​ ​ ​ ​ (1,604 ) ​ ​ ​ ​ ​ (1,178 ) ​ ​
Proceeds from new common shares issued
​ ​ ​ ​ 158 ​ ​ ​ ​ ​ — ​ ​
Dividends paid
​ ​ ​ ​ (7,791 ) ​ ​ ​ ​ ​ — ​ ​
Net cash provided (used) by financing activities
​ ​ ​ ​ (9,237 ) ​ ​ ​ ​ ​ (3,178 ) ​ ​
Effect of exchange rate changes on cash
​ ​ ​ ​ (739 ) ​ ​ ​ ​ ​ (357 ) ​ ​
Net increase (decrease) in cash and cash equivalents
​ ​ ​ ​ 8,868 ​ ​ ​ ​ ​ 3,105 ​ ​
Cash and cash equivalents at beginning of period
​ ​ ​ ​ 11,821 ​ ​ ​ ​ ​ 27,369 ​ ​
Cash and cash equivalents at end of period
​ ​ ​ $ 20,689 ​ ​ ​ ​ $ 30,474 ​ ​
Non-cash investing and financing activities ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Capital/leasehold improvements
​ ​ ​ ​ — ​ ​ ​ ​ ​ 1,315 ​ ​
The accompanying notes are an integral part of these consolidated financial statements
6
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except per share amounts)
(unaudited)
1.
Description of Business
​
Phibro Animal Health Corporation (“Phibro” or “PAHC”) and its subsidiaries (together, the “Company”) is a diversified global developer, manufacturer and marketer of a broad range of animal health and mineral nutrition products to the poultry, swine, cattle, dairy, aquaculture and ethanol markets. The Company is also a manufacturer and marketer of performance products for use in the personal care, automotive, industrial chemical and chemical catalyst industries. Unless otherwise indicated or the context requires otherwise, references in this report to “we,” “our,” “us,” “the Company” and similar expressions refer to Phibro and its subsidiaries.
The unaudited consolidated financial information for the three and six months ended December 31, 2014 and 2013, is presented on the same basis as the financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2014 (the “Annual Report”). In the opinion of management, these financial statements include all adjustments necessary for a fair statement of financial position, results of operations and cash flows for the interim periods, and the adjustments are of a normal and recurring nature. The financial results for any interim period are not necessarily indicative of the results for the full year. The consolidated balance sheet information as of June 30, 2014, was derived from the audited consolidated financial statements, but does not include all disclosures required by accounting principles generally accepted in the United States of America. The unaudited consolidated financial information should be read in conjunction with the consolidated financial statements and notes thereto included in the Annual Report.
The consolidated financial statements include the accounts of Phibro and all majority-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in the consolidated financial statements.
Certain reclassifications have been made to prior year amounts to conform to current year presentation.
2.
Summary of Significant Accounting Policies and New Accounting Standards
​
Our significant accounting policies are described in the notes to the consolidated financial statements included in our Annual Report. As of December 31, 2014, there have been no material changes to any of the significant accounting policies contained therein.
Net Income per Share and Weighted Average Shares
Basic net income per share is calculated by dividing net income by the weighted average number of common shares outstanding during the reporting period. Diluted net income per share is calculated by dividing net income by the weighted average number of common shares outstanding during the reporting period after giving effect to potential dilutive common shares resulting from the exercise of stock options and warrants. For the three and six month periods ended December 31, 2013, the stock options and warrant to purchase 1,885 shares of common stock had an exercise price greater than the estimated market value and were excluded from the calculation of diluted net income per share because the effect from the assumed exercise of these options and warrants was anti-dilutive.
​ ​ ​
Three Months
​ ​
Six Months
​
For the Periods Ended December 31
​ ​
2014
​ ​
2013
​ ​
2014
​ ​
2013
​
Net income
​ ​ ​ $ 15,405 ​ ​ ​ ​ $ 2,302 ​ ​ ​ ​ $ 35,886 ​ ​ ​ ​ $ 8,145 ​ ​
Weighted average number of shares – basic
​ ​ ​ ​ 38,957 ​ ​ ​ ​ ​ 30,458 ​ ​ ​ ​ ​ 38,928 ​ ​ ​ ​ ​ 30,458 ​ ​
Dilutive effect of stock options and warrant
​ ​ ​ ​ 856 ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ 762 ​ ​ ​ ​ ​ — ​ ​
Weighted average number of shares – diluted
​ ​ ​ ​ 39,813 ​ ​ ​ ​ ​ 30,458 ​ ​ ​ ​ ​ 39,690 ​ ​ ​ ​ ​ 30,458 ​ ​
Net income per share: ​ ​ ​ ​ ​
basic
​ ​ ​ $ 0.40 ​ ​ ​ ​ $ 0.08 ​ ​ ​ ​ $ 0.92 ​ ​ ​ ​ $ 0.27 ​ ​
diluted
​ ​ ​ $ 0.39 ​ ​ ​ ​ $ 0.08 ​ ​ ​ ​ $ 0.90 ​ ​ ​ ​ $ 0.27 ​ ​
7
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
New Accounting Standards
ASU 2014-08, Presentation of Financials (Topic 205) and Property, Plant, and Equipment (Topic 360): Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity, changes the criteria for reporting a discontinued operation while enhancing disclosures. Under the new guidance, a disposal of a component of an entity or group of components of an entity that represents a strategic shift that has, or will have, a major effect on operations and financial results is a discontinued operation when any of the following occurs: (i) it meets the criteria to be classified as held for sale, (ii) it is disposed of by sale, or (iii) it is disposed of other than by sale. Also, a business that, on acquisition, meets the criteria to be classified as held for sale is reported in discontinued operations. Additionally, the new guidance requires expanded disclosures about discontinued operations, as well as disclosure of the pre-tax profit or loss attributable to a disposal of an individually significant component of an entity that does not qualify for discontinued operations presentation. The guidance is effective prospectively for all disposals (or classifications as held for sale) of components of an entity and all businesses that, on acquisition, are classified as held for sale, that occur within annual periods beginning on or after December 15, 2014 and interim periods within those years. We do not expect adoption of this guidance will have a material effect on our consolidated financial statements.
ASU 2014-09, Revenue from Contracts with Customers (Topic 606), establishes principles for the recognition of revenue from contracts with customers. The underlying principle is to identify the performance obligations of a contract, allocate the revenue to each performance obligation and then to recognize revenue when the company satisfies a specific performance obligation of the contract. ASU 2014-09 is effective for interim and annual periods beginning after December 15, 2016. Early adoption is not permitted. The guidance should be applied retrospectively to each prior reporting period presented. We are currently evaluating the impact that adopting this guidance will have on our consolidated financial statements.
ASU 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern, requires management to assess an entity’s ability to continue as a going concern, and to provide related footnote disclosures in certain circumstances. Management will need to assess if there is substantial doubt about an entity’s ability to continue as a going concern within one year after the issuance date. Management will need to consider relevant conditions that are known and reasonably knowable at the issuance date. Substantial doubt exists if it is probable that the entity will be unable to meet its obligations within one year after the issuance date. Under the new standard, the definition of substantial doubt incorporates a likelihood threshold of  “probable” similar to the current use of that term in U.S. Generally Accepted Accounting Principles (“GAAP”) for loss contingencies. ASU 2014-15 will be effective for annual periods ending after December 15, 2016. Earlier adoption is permitted. We do not expect adoption of this guidance will have a material effect on our consolidated financial statements.
3.
Subsequent Event
​
In January 2015, we entered into a Collaboration and Distribution Agreement (the “Collaboration Agreement”) with MJ Biologics, Inc. (“MJB”), pursuant to which we and MJB will collaborate on the development of certain animal vaccines and MJB granted us an exclusive license to manufacture and distribute, in North America, any vaccine product currently being developed or sold by MJB or any other product which is developed under the Collaboration Agreement. We will reimburse MJB’s cost of goods, make certain minimum base payments of  $200 per month to MJB during the term of the Collaboration Agreement, subject to certain offset provisions, and pay 50% of all gross margins over $400 per month to MJB.
We also entered into a Technology License Agreement (the “License Agreement”) with MJB, pursuant to which MJB granted us an exclusive license to develop, manufacture and commercialize, outside of North America, vaccine products using MJB’s patents and know-how. We will make quarterly royalty payments to MJB in an amount equal to a specified percentage of net sales outside of North America.
8
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
Unless otherwise terminated due to material breach or bankruptcy, the Collaboration Agreement and the License Agreement will continue in effect until the earlier of the Closing Date of the Purchase Agreement described below or the termination of the Purchase Agreement without the Closing occurring thereunder.
We also entered into an Intellectual Property Purchase Agreement (the “Purchase Agreement”) with MJB, pursuant to which we will acquire the intellectual property and certain other assets comprising MJB’s business relating to animal vaccines. The closing date of the acquisition (the “Closing” or the “Closing Date”) is anticipated to occur on or before January 1, 2021, subject to certain closing conditions. Upon the occurrence of certain events, the Closing of the Purchase Agreement will occur prior to the scheduled Closing Date.
Under the terms of the Purchase Agreement, we made an upfront payment to MJB of  $5,000 and agreed to pay MJB a “Closing Payment” at Closing in an amount to be calculated based on the worldwide net sales of MJB’s vaccines for the 12 months immediately prior to the Closing Date. The Closing Payment will not be less than $10,000, subject to offset in certain limited circumstances. In addition, MJB will be entitled to receive earn-out payments, from the Closing Date through December 31, 2030, based on (i) a single-digit percentage of the net sales of any “Royalty Product” (as defined in the License Agreement) that we sell commercially in North America, and (ii) a single-digit percentage of the net sales of any Royalty Product that is sold commercially outside of North America by us at the time of or after the Closing.
We also made a loan of  $5,000 to MJB’s sole shareholder, which matures on the Closing Date. The loan bears interest at a variable rate equal to LIBOR plus 300 basis points. The unpaid principal amount of the loan, together with all outstanding and unpaid interest, will be due and payable at Closing or over a period ending January 2025 in the event of a termination of the Purchase Agreement by us or upon the occurrence of certain customary events of default.
4.
Statements of Operations—Additional Information
​
​ ​ ​
Three Months
​ ​
Six Months
​
For the Periods Ended December 31
​ ​
2014
​ ​
2013
​ ​
2014
​ ​
2013
​
Depreciation and amortization ​ ​ ​ ​ ​
Depreciation of property, plant and equipment
​ ​ ​ $ 4,123 ​ ​ ​ ​ $ 4,106 ​ ​ ​ ​ $ 8,351 ​ ​ ​ ​ $ 7,958 ​ ​
Amortization of intangible assets
​ ​ ​ ​ 1,057 ​ ​ ​ ​ ​ 1,186 ​ ​ ​ ​ ​ 2,126 ​ ​ ​ ​ ​ 2,535 ​ ​
Amortization of other assets
​ ​ ​ ​ 61 ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ 117 ​ ​ ​ ​ ​ — ​ ​
​ ​ ​ ​ $ 5,241 ​ ​ ​ ​ $ 5,292 ​ ​ ​ ​ $ 10,594 ​ ​ ​ ​ $ 10,493 ​ ​
​
5.
Balance Sheets—Additional Information
​
As of
​ ​
December 31,
2014
​ ​
June 30,
2014
​
Inventories ​ ​ ​
Raw materials
​ ​ ​ $ 48,844 ​ ​ ​ ​ $ 44,306 ​ ​
Work-in-process
​ ​ ​ ​ 7,470 ​ ​ ​ ​ ​ 7,518 ​ ​
Finished goods
​ ​ ​ ​ 88,544 ​ ​ ​ ​ ​ 91,360 ​ ​
​ ​ ​ ​ $ 144,858 ​ ​ ​ ​ $ 143,184 ​ ​
Goodwill ​ ​ ​
Balance at beginning and end of period
​ ​ ​ $ 12,613 ​ ​ ​ ​ $ 12,613 ​ ​
​
9
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
As of
​ ​
December 31,
2014
​ ​
June 30,
2014
​
Accrued expenses and other current liabilities ​ ​ ​
Employee related accruals
​ ​ ​ $ 15,507 ​ ​ ​ ​ $ 20,813 ​ ​
Commissions and rebates
​ ​ ​ ​ 4,448 ​ ​ ​ ​ ​ 2,973 ​ ​
Insurance related
​ ​ ​ ​ 1,269 ​ ​ ​ ​ ​ 1,395 ​ ​
Professional fees
​ ​ ​ ​ 4,181 ​ ​ ​ ​ ​ 4,229 ​ ​
Deferred consideration on acquisitions
​ ​ ​ ​ 1,449 ​ ​ ​ ​ ​ 1,420 ​ ​
Product liability claims
​ ​ ​ ​ — ​ ​ ​ ​ ​ 5,286 ​ ​
Other accrued liabilities
​ ​ ​ ​ 14,934 ​ ​ ​ ​ ​ 13,745 ​ ​
​ ​ ​ ​ $ 41,788 ​ ​ ​ ​ $ 49,861 ​ ​
​
As of
​ ​
December 31,
2014
​ ​
June 30,
2014
​
Accumulated other comprehensive income (loss) ​ ​ ​
Derivative instruments
​ ​ ​ $ (337 ) ​ ​ ​ ​ $ 386 ​ ​
Foreign currency translation adjustment
​ ​ ​ ​ (18,747 ) ​ ​ ​ ​ ​ (1,409 ) ​ ​
Unrecognized net pension gains (losses)
​ ​ ​ ​ (15,961 ) ​ ​ ​ ​ ​ (16,663 ) ​ ​
Income tax (provision) benefit on derivative instruments
​ ​ ​ ​ 63 ​ ​ ​ ​ ​ 63 ​ ​
Income tax (provision) benefit on pension gains (losses)
​ ​ ​ ​ (2,437 ) ​ ​ ​ ​ ​ (2,437 ) ​ ​
​ ​ ​ ​ $ (37,419 ) ​ ​ ​ ​ $ (20,060 ) ​ ​
​
We evaluate our investments in equity method investees for impairment if circumstances indicate that the fair value of the investment may be impaired. The assets underlying a $4,427 equity investment are currently idled; we have concluded the investment is not currently impaired, based on expected future operating cash flows and/or disposal value.
6.
Debt
​
Revolving Credit Facility and Term B Loan
Borrowings under the Revolving Credit Facility and Term B Loan (the “Credit Facilities”) bear interest based on a fluctuating rate equal to the sum of an applicable margin and, at the Company’s election from time to time, either (1) a Eurocurrency rate determined by reference to LIBOR with a term as selected by the Company, of one day or one, two, three or six months (or twelve months or any shorter amount of time if consented to by all of the lenders under the applicable loan), or (2) a base rate determined by reference to the highest of  (a) the rate as publicly announced from time to time by Bank of America as its “prime rate,” (b) the federal funds effective rate plus 0.50% and (c) one-month LIBOR plus 1.00%. The Revolving Credit Facility has applicable margins equal to 2.50% or 2.75% in the case of LIBOR loans and 1.50% or 1.75% in the case of base rate loans; the applicable margins are based on the First Lien Net Leverage Ratio (as defined in the agreement). The Term B Loan has applicable margins equal to 3.00% in the case of LIBOR loans and 2.00% in the case of base rate loans. The LIBOR rate on the Term B Loan is subject to a floor of 1.00%. The rate of interest on the Term B Loan was 4.00% at December 31, 2014.
As of December 31, 2014, we had no outstanding borrowings under the Revolving Credit Facility and had outstanding letters of credit and other commitments of  $17,205, leaving $82,795 available for borrowings and letters of credit under the Revolving Credit Facility. We obtain letters of credit in connection with certain regulatory and insurance obligations, inventory purchases and other contractual obligations. The terms of these letters of credit are all less than one year.
The Revolving Credit Facility requires, among other things, the maintenance of a maximum consolidated First Lien Net Leverage Ratio calculated on a trailing four quarter basis, and contains an acceleration clause should an event of default (as defined in the agreement) occur. The permitted maximum
10
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
ratio is 4.50:1.00 for measurement periods through June 30, 2015, and 4.25:1.00 for measurements periods thereafter. As of December 31, 2014, we were in compliance with the covenants of the Credit Facilities.
Long-Term Debt
As of
​ ​
December 31,
2014
​ ​
June 30,
2014
​
Term B loan due April 15, 2021
​ ​ ​ $ 288,550 ​ ​ ​ ​ $ 290,000 ​ ​
Capitalized lease obligations
​ ​ ​ ​ 43 ​ ​ ​ ​ ​ 94 ​ ​
​ ​ ​ ​ ​ 288,593 ​ ​ ​ ​ ​ 290,094 ​ ​
Unamortized debt discount
​ ​ ​ ​ (652 ) ​ ​ ​ ​ ​ (703 ) ​ ​
​ ​ ​ ​ ​ 287,941 ​ ​ ​ ​ ​ 289,391 ​ ​
Less: current maturities
​ ​ ​ ​ (2,828 ) ​ ​ ​ ​ ​ (2,969 ) ​ ​
​ ​ ​ ​ $ 285,113 ​ ​ ​ ​ $ 286,422 ​ ​
​
7.
Warrant and Dividends
​
Class B Common Stock Warrant
On August 1, 2014, a common stock purchase warrant for the purchase of 387 shares of Class B common stock, held by BFI Co., LLC (“BFI”), was automatically exercised at the exercise price of  $11.83 per share on a cashless basis, resulting in a net issuance of 164 shares of Class B common stock to BFI.
Dividends
In September 2014 and December 2014, we paid $0.10 per share quarterly dividends to holders of our Class A and Class B common stock. We intend to pay regular quarterly dividends to holders of our Class A and Class B common stock out of assets legally available for this purpose. Our future ability to pay dividends will depend upon our results of operations, financial condition, capital requirements, our ability to obtain funds from our subsidiaries and other factors that our Board of Directors deems relevant. Additionally, the terms of our current and any future agreements governing our indebtedness could limit our ability to pay dividends or make other distributions.
8.
Employee Benefit Plans
​
The Company maintains a noncontributory defined benefit pension plan for all domestic nonunion employees employed on or prior to December 31, 2013, who meet certain requirements of age, length of service and hours worked per year. Plan benefits are based upon years of service and average compensation, as defined within the plan.
Net periodic pension expense was:
​ ​ ​
Three Months
​ ​
Six Months
​
For the Periods Ended December 31
​ ​
2014
​ ​
2013
​ ​
2014
​ ​
2013
​
Service cost – benefits earned during the period
​ ​ ​ $ 656 ​ ​ ​ ​ $ 604 ​ ​ ​ ​ $ 1,477 ​ ​ ​ ​ $ 1,308 ​ ​
Interest cost on benefit obligation
​ ​ ​ ​ 574 ​ ​ ​ ​ ​ 577 ​ ​ ​ ​ ​ 1,309 ​ ​ ​ ​ ​ 1,218 ​ ​
Expected return on plan assets
​ ​ ​ ​ (648 ) ​ ​ ​ ​ ​ (577 ) ​ ​ ​ ​ ​ (1,414 ) ​ ​ ​ ​ ​ (1,275 ) ​ ​
Amortization of net actuarial loss and prior service costs
​ ​ ​ ​ 417 ​ ​ ​ ​ ​ 226 ​ ​ ​ ​ ​ 702 ​ ​ ​ ​ ​ 429 ​ ​
Net periodic pension expense
​ ​ ​ $ 999 ​ ​ ​ ​ $ 830 ​ ​ ​ ​ $ 2,074 ​ ​ ​ ​ $ 1,680 ​ ​
​
11
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
9.
Income Taxes
​
The tax provision is comprised primarily of income taxes relating to profitable foreign jurisdictions, partially offset by a year to date benefit of  $1,218 from the recognition of certain previously unrecognized tax benefits. The provision for income taxes on domestic pre-tax income was substantially offset by the utilization of domestic net operating losses that previously had been offset by a valuation allowance.
We review the realizability of our deferred tax assets on a quarterly basis, or whenever events or changes in circumstances indicate that a review is required. We continue to maintain a full valuation allowance against net deferred tax assets from domestic and certain foreign jurisdictions. We have evaluated the positive and negative evidence relating to the potential reversal of the valuation allowance and have determined that at this time we will continue to maintain a full valuation allowance. In future quarters, we will continue to evaluate the need to maintain the valuation allowance and, to the extent that positive evidence trends continue, a significant portion of the valuation allowance could be released in future periods.
We have not provided for United States or additional foreign taxes on undistributed earnings of foreign subsidiaries, which earnings have been or are intended to be indefinitely reinvested. It is not practicable at this time to determine the amount of income tax liability that would result should such earnings be repatriated. Income taxes are not provided for foreign currency translation adjustments relating to investments in international subsidiaries that will be held indefinitely.
10.
Commitments and Contingencies
​
Environmental
Our operations and properties are subject to extensive federal, state, local and foreign laws and regulations, including those governing pollution; protection of the environment; the use, management, and release of hazardous materials, substances and wastes; air emissions; greenhouse gas emissions; water use, supply and discharges; the investigation and remediation of contamination; the manufacture, distribution, and sale of regulated materials, including pesticides; the importing, exporting and transportation of products; and the health and safety of our employees (collectively, “Environmental Laws”). As such, the nature of our current and former operations exposes us to the risk of claims with respect to such matters, including fines, penalties, and remediation obligations that may be imposed by regulatory authorities. Under certain circumstances, we might be required to curtail operations until a particular problem is remedied. Known costs and expenses under Environmental Laws incidental to ongoing operations, including the cost of litigation proceedings relating to environmental matters, are generally included within operating results. Potential costs and expenses may also be incurred in connection with the repair or upgrade of facilities to meet existing or new requirements under Environmental Laws or to investigate or remediate potential or actual contamination and from time to time we establish reserves for such contemplated investigation and remediation costs. In many instances, the ultimate costs under Environmental Laws and the time period during which such costs are likely to be incurred are difficult to predict.
While we believe that our operations are currently in material compliance with Environmental Laws, we have, from time to time, received notices of violation from governmental authorities, and have been involved in civil or criminal action for such violations. Additionally, at various sites, our subsidiaries are engaged in continuing investigation, remediation and/or monitoring efforts to address contamination associated with historic operations of the sites. We devote considerable resources to complying with Environmental Laws and managing environmental liabilities. We have developed programs to identify requirements under, and maintain compliance with Environmental Laws; however, we cannot predict with certainty the effect of increased and more stringent regulation on our operations, future capital expenditure requirements, or the cost of compliance.
The nature of our current and former operations exposes us to the risk of claims with respect to environmental matters and we cannot assure you we will not incur material costs and liabilities in
12
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
connection with such claims. Based upon our experience to date, we believe that the future cost of compliance with existing Environmental Laws, and liabilities for known environmental claims pursuant to such Environmental Laws, will not have a material adverse effect on our financial position, results of operations, cash flows or liquidity.
The U.S. Environmental Protection Agency (the “EPA”) is investigating and planning for the remediation of offsite contaminated groundwater that has migrated from the Omega Chemical Corporation Superfund Site (“Omega Chemical Site”), which is upgradient of Phibro-Tech’s Santa Fe Springs, California facility. The EPA has named Phibro-Tech and certain other subsidiaries of PAHC as potentially responsible parties (“PRPs”) due to groundwater contamination from Phibro-Tech’s Santa Fe Springs facility that has allegedly commingled with contaminated groundwater from the Omega Chemical Site. In September 2012, the EPA notified approximately 140 PRPs, including Phibro-Tech and the other subsidiaries, that they have been identified as potentially responsible for remedial action for the groundwater plume affected by the Omega Chemical Site and for EPA oversight and response costs. Phibro-Tech contends that groundwater contamination at its site is due to historical operations that pre-date Phibro-Tech and/or contaminated groundwater that has migrated from upgradient properties. In addition, a successor to a prior owner of the Phibro-Tech site has asserted that PAHC and Phibro-Tech are obligated to provide indemnification for its potential liability and defense costs relating to the groundwater plume affected by the Omega Chemical Site. Phibro-Tech has vigorously contested this position and has asserted that the successor to the prior owner is required to indemnify Phibro-Tech for its potential liability and defense costs. Furthermore, a nearby property owner has filed a complaint in the Superior Court of the State of California against many of the PRPs allegedly associated with the groundwater plume affected by the Omega Chemical Site (including Phibro-Tech) for alleged contamination of groundwater underneath its property; a group of companies that sent chemicals to the Omega Chemical Site for processing and recycling has filed a complaint under CERCLA in the United States District Court for the Central District of California against many of the PRPs allegedly associated with the groundwater plume affected by the Omega Chemical Site (including Phibro-Tech) for contribution toward past and future costs associated with the investigation and remediation of the groundwater plume affected by the Omega Chemical Site; and that same group of companies has served Phibro-Tech with a Notice of Endangerment and Intent to Sue Pursuant to RCRA § 7002(a)(1)(B) seeking to abate alleged imminent and substantial endangerment to health or the environment resulting from the lack of adequate offsite monitoring and groundwater source control associated with former and/or continuing operations at Phibro-Tech’s Santa Fe Springs facility. Due to the ongoing nature of the EPA’s investigation and Phibro-Tech’s dispute with the prior owner’s successor, at this time we cannot predict with any degree of certainty what, if any, liability Phibro-Tech or the other subsidiaries may ultimately have for investigation, remediation and the EPA oversight and response costs associated with the affected groundwater plume.
Based upon information available, to the extent such costs can be estimated with reasonable certainty, we estimated the cost for further investigation and remediation of identified soil and groundwater problems at operating sites, closed sites and third-party sites, and closure costs for closed sites, to be approximately $6,984 and $7,273 at December 31, 2014, and June 30, 2014, respectively, which is included in current and long-term liabilities on the consolidated balance sheets. However, future events, such as new information, changes in existing Environmental Laws or their interpretation, and more vigorous enforcement policies of regulatory agencies, may give rise to additional expenditures or liabilities that could be material. For all purposes of the discussion under this caption and elsewhere in this report, it should be noted that we take and have taken the position that neither PAHC nor any of our subsidiaries is liable for environmental or other claims made against one or more of our other subsidiaries or for which any of such other subsidiaries may ultimately be responsible.
Claims and Litigation
PAHC and its subsidiaries are party to a number of claims and lawsuits arising out of the normal course of business including product liabilities, payment disputes and governmental regulation. Certain of these actions seek damages in various amounts. In many cases, such claims are covered by insurance. We believe that none of the claims or pending lawsuits, either individually or in the aggregate, will have a material adverse effect on our financial position, results of operations, cash flows or liquidity.
13
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
11.
Derivatives
​
We monitor our exposure to commodity prices, interest rates and foreign currency exchange rates, and use derivatives to manage certain of these risks. We designate derivatives as a hedge of a forecasted transaction or of the variability of the cash flows to be received or paid in the future related to a recognized asset or liability (cash flow hedge). We record the portion of the changes in the expected cash flows related to a recognized asset or liability (the effective portion) in accumulated other comprehensive income (loss). As the hedged item is realized, we report the gain or loss included in accumulated other comprehensive income (loss) in the consolidated statements of operations on the same line as the hedged item. We immediately recognize in the consolidated statements of operations in the same line as the hedged item, the portion of the changes in fair value of derivatives used as cash flow hedges that is not offset by changes in the expected cash flows related to a recognized asset or liability (the ineffective portion).
We routinely assess whether the derivatives used to hedge transactions are effective. If we determine a derivative ceases to be an effective hedge, we discontinue hedge accounting, and recognize in the consolidated statements of operations, in the period the derivative no longer qualifies as a hedge, any gains or losses on the derivative.
We record derivatives at fair value in prepaid expenses and other current assets or accrued expenses and other current liabilities in the consolidated balance sheets. We determine the fair value of derivative instruments based upon pricing models using observable market inputs for these types of financial instruments (level 2 inputs per ASC 820).
At December 31, 2014, the following outstanding derivatives were designated and effective as cash flow hedges:
Instrument
​ ​
Hedge
​ ​
Notional
Amount at
December 31,
2014
​ ​
Fair value as of
​
​
December 31,
2014
​ ​
June 30,
2014
​
Options
​ ​
Brazilian Real calls
​ ​ ​ R$ 117,000 ​ ​ ​ ​ $ 385 ​ ​ ​ ​ $ 432 ​ ​
Options
​ ​
Brazilian Real puts
​ ​ ​ (R$ 117,000 ) ​ ​ ​ ​ $ (722 ) ​ ​ ​ ​ $ (46 ) ​ ​
The unrecognized gains (losses) at December 31, 2014, are unrealized and will change depending on future exchange rates until the underlying contracts mature. Of the ($337) of unrecognized gains (losses) on derivative instruments included in accumulated other comprehensive income (loss) at December 31, 2014, we anticipate ($312) of the current fair value would be recorded in earnings within the next twelve months. We recognize gains (losses) on derivative instruments as a component of cost of goods sold when the hedged item is sold. We hedge forecasted transactions for periods not exceeding the next twenty-four months.
12.
Fair Value Measurements
​
In assessing the fair value of financial instruments at December 31, 2014, we used a variety of methods and assumptions which were based on estimates of market conditions and risks existing at the time.
Current Assets and Liabilities
We consider the carrying amounts of current assets and current liabilities, except the current portion of long-term debt, to be representative of their fair value because of the current nature of these items.
Long Term Debt
We estimated the fair value of the Term B Loan based on quoted broker prices (level 2 inputs per ASC 820).
As of
​ ​
December 31,
2014
​ ​
June 30,
2014
​
Fair values ​ ​ ​
Term B Loan
​ ​ ​ $ 283,500 ​ ​ ​ ​ $ 289,638 ​ ​
14
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
13.
Business Segments
​
The Animal Health segment manufactures and markets products for the poultry, swine, cattle, dairy, aquaculture and ethanol markets. The business includes net sales of medicated feed additives and other related products, nutritional specialty products and vaccines. The Mineral Nutrition segment manufactures and markets trace minerals for the cattle, swine, poultry and pet food markets. The Performance Products segment manufactures and markets a variety of products for use in the personal care, automotive, industrial chemical and chemical catalyst industries.
We evaluate performance and allocate resources based on the Animal Health, Mineral Nutrition and Performance Products segments. Certain of our costs and assets are not directly attributable to these segments. We do not allocate such items to the principal segments because they are not used to evaluate their operating results or financial position. Corporate costs include the departmental operating costs of the Board of Directors, the Chairman, President and Chief Executive Officer, the Chief Operating Officer, the Chief Financial Officer, the Senior Vice President and General Counsel, the Senior Vice President of Human Resources, the Chief Information Officer and the Executive Vice President of Corporate Strategy. Costs include the executives and their staffs and include compensation and benefits, outside services, professional fees and office space. Assets include cash and cash equivalents, debt issue costs and certain other assets.
We evaluate performance of our segments based on Adjusted EBITDA. We define Adjusted EBITDA as EBITDA plus (a) (income) loss from, and disposal of, discontinued operations, (b) other expense or less other income, as separately reported on our consolidated statements of operations, including foreign currency gains and losses and loss on extinguishment of debt, and (c) certain items that we consider to be unusual or non-recurring. We define EBITDA as net income plus (i) interest expense, net, (ii) provision for income taxes or less benefit for income taxes and (iii) depreciation and amortization.
The accounting policies of our segments are the same as those described in the summary of significant accounting policies included in the “—Summary of Significant Accounting Policies and New Accounting Standards.”
​ ​ ​
Three Months
​ ​
Six Months
​
For the Periods Ended December 31
​ ​
2014
​ ​
2013
​ ​
2014
​ ​
2013
​
Net sales ​ ​ ​ ​ ​
Animal Health
​ ​ ​ $ 118,785 ​ ​ ​ ​ $ 107,966 ​ ​ ​ ​ $ 236,010 ​ ​ ​ ​ $ 209,137 ​ ​
Mineral Nutrition
​ ​ ​ ​ 58,742 ​ ​ ​ ​ ​ 50,633 ​ ​ ​ ​ ​ 114,189 ​ ​ ​ ​ ​ 96,819 ​ ​
Performance Products
​ ​ ​ ​ 11,161 ​ ​ ​ ​ ​ 14,143 ​ ​ ​ ​ ​ 25,947 ​ ​ ​ ​ ​ 29,014 ​ ​
​ ​ ​ ​ $ 188,688 ​ ​ ​ ​ $ 172,742 ​ ​ ​ ​ $ 376,146 ​ ​ ​ ​ $ 334,970 ​ ​
Adjusted EBITDA ​ ​ ​ ​ ​
Animal Health
​ ​ ​ $ 28,296 ​ ​ ​ ​ $ 24,522 ​ ​ ​ ​ $ 60,750 ​ ​ ​ ​ $ 48,629 ​ ​
Mineral Nutrition
​ ​ ​ ​ 3,754 ​ ​ ​ ​ ​ 2,878 ​ ​ ​ ​ ​ 7,233 ​ ​ ​ ​ ​ 5,338 ​ ​
Performance Products
​ ​ ​ ​ 162 ​ ​ ​ ​ ​ 1,103 ​ ​ ​ ​ ​ 1,198 ​ ​ ​ ​ ​ 2,199 ​ ​
Corporate
​ ​ ​ ​ (7,184 ) ​ ​ ​ ​ ​ (6,193 ) ​ ​ ​ ​ ​ (13,695 ) ​ ​ ​ ​ ​ (12,258 ) ​ ​
​ ​ ​ ​ $ 25,028 ​ ​ ​ ​ $ 22,310 ​ ​ ​ ​ $ 55,486 ​ ​ ​ ​ $ 43,908 ​ ​
Reconciliation of Adjusted EBITDA to income before income taxes
​ ​ ​ ​ ​
Adjusted EBITDA
​ ​ ​ $ 25,028 ​ ​ ​ ​ $ 22,310 ​ ​ ​ ​ $ 55,486 ​ ​ ​ ​ $ 43,908 ​ ​
Depreciation and amortization
​ ​ ​ ​ (5,241 ) ​ ​ ​ ​ ​ (5,292 ) ​ ​ ​ ​ ​ (10,594 ) ​ ​ ​ ​ ​ (10,493 ) ​ ​
Interest expense, net
​ ​ ​ ​ (3,515 ) ​ ​ ​ ​ ​ (8,719 ) ​ ​ ​ ​ ​ (7,005 ) ​ ​ ​ ​ ​ (17,454 ) ​ ​
Foreign currency gains (losses), net
​ ​ ​ ​ 1,018 ​ ​ ​ ​ ​ (1,165 ) ​ ​ ​ ​ ​ 2,222 ​ ​ ​ ​ ​ (1,813 ) ​ ​
Income before income taxes
​ ​ ​ $ 17,290 ​ ​ ​ ​ $ 7,134 ​ ​ ​ ​ $ 40,109 ​ ​ ​ ​ $ 14,148 ​ ​
​
15
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
As of
​ ​
December 31,
2014
​ ​
June 30,
2014
​
Identifiable assets ​ ​ ​
Animal Health
​ ​ ​ $ 348,288 ​ ​ ​ ​ $ 361,376 ​ ​
Mineral Nutrition
​ ​ ​ ​ 61,795 ​ ​ ​ ​ ​ 57,460 ​ ​
Performance Products
​ ​ ​ ​ 21,869 ​ ​ ​ ​ ​ 23,429 ​ ​
Corporate
​ ​ ​ ​ 35,725 ​ ​ ​ ​ ​ 30,058 ​ ​
​ ​ ​ ​ $ 467,677 ​ ​ ​ ​ $ 472,323 ​ ​
​
All goodwill is included in the Animal Health segment. The Animal Health segment includes advances to and investment in equity method investee of  $4,427 and $5,140 as of December 31, 2014, and June 30, 2014, respectively. The Performance Products segment includes an investment in equity method investee of  $502 and $479 as of December 31, 2014, and June 30, 2014, respectively. Corporate includes all cash and cash equivalents.
16
Item 2.
Management’s Discussion and Analysis of Financial Condition and Results of Operations
​
Introduction
Our management’s discussion and analysis of financial condition and results of operations (“MD&A”) is provided to assist readers in understanding our performance, as reflected in the results of our operations, our financial condition and our cash flows. The following discussion summarizes the significant factors affecting our consolidated operating results, financial condition, liquidity and cash flows as of and for the periods presented below. This MD&A should be read in conjunction with our consolidated financial statements and related notes thereto included elsewhere in this document.
Overview of our business
Phibro Animal Health Corporation is a global diversified animal health and mineral nutrition company. We develop, manufacture and market products for a broad range of food animals including poultry, swine, beef and dairy cattle and aquaculture. Our products help prevent, control and treat diseases, enhance nutrition to help improve health and performance and contribute to balanced mineral nutrition. In addition to animal health and mineral nutrition products, we manufacture and market specific ingredients for use in the personal care, automotive, industrial chemical and chemical catalyst industries.
Analysis of the consolidated statements of operations
Summary Results of Operations
​ ​ ​
Three Months
​ ​
Six Months
​
For the Periods Ended December 31
​ ​
2014
​ ​
2013
​ ​
Change
​ ​
2014
​ ​
2013
​ ​
Change
​
​ ​ ​
(in thousands, except per share)
​ ​
(in thousands, except per share)
​
Net sales
​ ​ ​ $ 188,688 ​ ​ ​ ​ $ 172,742 ​ ​ ​ ​ $ 15,946 ​ ​ ​ ​
​
9 %
​ ​ ​ ​ $ 376,146 ​ ​ ​ ​ $ 334,970 ​ ​ ​ ​ $ 41,176 ​ ​ ​ ​
​
12 %
​ ​
Gross profit
​ ​ ​ ​ 56,085 ​ ​ ​ ​ ​ 51,156 ​ ​ ​ ​ ​ 4,929 ​ ​ ​ ​
​
10 %
​ ​ ​ ​ ​ 116,414 ​ ​ ​ ​ ​ 100,668 ​ ​ ​ ​ ​ 15,746 ​ ​ ​ ​
​
16 %
​ ​
Selling, general and administrative expenses
​ ​ ​ ​ 36,298 ​ ​ ​ ​ ​ 34,138 ​ ​ ​ ​ ​ 2,160 ​ ​ ​ ​
​
6 %
​ ​ ​ ​ ​ 71,522 ​ ​ ​ ​ ​ 67,253 ​ ​ ​ ​ ​ 4,269 ​ ​ ​ ​
​
6 %
​ ​
Operating income
​ ​ ​ ​ 19,787 ​ ​ ​ ​ ​ 17,018 ​ ​ ​ ​ ​ 2,769 ​ ​ ​ ​
​
16 %
​ ​ ​ ​ ​ 44,892 ​ ​ ​ ​ ​ 33,415 ​ ​ ​ ​ ​ 11,477 ​ ​ ​ ​
​
34 %
​ ​
Interest expense, net
​ ​ ​ ​ 3,515 ​ ​ ​ ​ ​ 8,719 ​ ​ ​ ​ ​ (5,204 ) ​ ​ ​ ​
​
(60 )%
​ ​ ​ ​ ​ 7,005 ​ ​ ​ ​ ​ 17,454 ​ ​ ​ ​ ​ (10,449 ) ​ ​ ​ ​
​
(60 )%
​ ​
Foreign currency (gains) losses, net
​ ​ ​ ​ (1,018 ) ​ ​ ​ ​ ​ 1,165 ​ ​ ​ ​ ​ (2,183 ) ​ ​ ​ ​
​
*
​ ​ ​ ​ ​ (2,222 ) ​ ​ ​ ​ ​ 1,813 ​ ​ ​ ​ ​ (4,035 ) ​ ​ ​ ​
​
*
​ ​
Income before income taxes
​ ​ ​ ​ 17,290 ​ ​ ​ ​ ​ 7,134 ​ ​ ​ ​ ​ 10,156 ​ ​ ​ ​
​
142 %
​ ​ ​ ​ ​ 40,109 ​ ​ ​ ​ ​ 14,148 ​ ​ ​ ​ ​ 25,961 ​ ​ ​ ​
​
183 %
​ ​
Provision for income taxes
​ ​ ​ ​ 1,885 ​ ​ ​ ​ ​ 4,832 ​ ​ ​ ​ ​ (2,947 ) ​ ​ ​ ​
​
(61 )%
​ ​ ​ ​ ​ 4,223 ​ ​ ​ ​ ​ 6,003 ​ ​ ​ ​ ​ (1,780 ) ​ ​ ​ ​
​
(30 )%
​ ​
Net income
​ ​ ​ $ 15,405 ​ ​ ​ ​ $ 2,302 ​ ​ ​ ​ $ 13,103 ​ ​ ​ ​
​
569 %
​ ​ ​ ​ $ 35,886 ​ ​ ​ ​ $ 8,145 ​ ​ ​ ​ $ 27,741 ​ ​ ​ ​
​
341 %
​ ​
Net income per share ​ ​ ​ ​ ​ ​ ​ ​ ​
basic
​ ​ ​ $ 0.40 ​ ​ ​ ​ $ 0.08 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ $ 0.92 ​ ​ ​ ​ $ 0.27 ​ ​ ​ ​
diluted
​ ​ ​ $ 0.39 ​ ​ ​ ​ $ 0.08 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ $ 0.90 ​ ​ ​ ​ $ 0.27 ​ ​ ​ ​
Weighted average number of shares outstanding
​ ​ ​ ​ ​ ​ ​ ​ ​
basic
​ ​ ​ ​ 38,957 ​ ​ ​ ​ ​ 30,458 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 38,928 ​ ​ ​ ​ ​ 30,458 ​ ​ ​ ​
diluted
​ ​ ​ ​ 39,813 ​ ​ ​ ​ ​ 30,458 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 39,690 ​ ​ ​ ​ ​ 30,458 ​ ​ ​ ​
Ratio to net sales ​ ​ ​ ​ ​ ​ ​ ​ ​
Gross profit
​ ​ ​ ​ 29.7 % ​ ​ ​ ​ ​ 29.6 % ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 30.9 % ​ ​ ​ ​ ​ 30.1 % ​ ​ ​ ​
Selling, general and administrative expenses
​ ​ ​ ​ 19.2 % ​ ​ ​ ​ ​ 19.8 % ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 19.0 % ​ ​ ​ ​ ​ 20.1 % ​ ​ ​ ​
Operating income
​ ​ ​ ​ 10.5 % ​ ​ ​ ​ ​ 9.9 % ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 11.9 % ​ ​ ​ ​ ​ 10.0 % ​ ​ ​ ​
Income before income taxes
​ ​ ​ ​ 9.2 % ​ ​ ​ ​ ​ 4.1 % ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 10.7 % ​ ​ ​ ​ ​ 4.2 % ​ ​ ​ ​
Net income
​ ​ ​ ​ 8.2 % ​ ​ ​ ​ ​ 1.3 % ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 9.5 % ​ ​ ​ ​ ​ 2.4 % ​ ​ ​ ​
Effective tax rate
​ ​ ​ ​ 10.9 % ​ ​ ​ ​ ​ 67.7 % ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 10.5 % ​ ​ ​ ​ ​ 42.4 % ​ ​ ​ ​
​
Certain amounts and percentages may reflect rounding adjustments
*
Calculation not meaningful
​
​
17
Changes in net sales from period to period primarily result from changes in volumes and average selling prices. Although a portion of our net sales is denominated in various currencies, the selling prices of the majority of our sales outside the United States are referenced in U.S. dollars, and as a result, our revenues are not significantly directly affected by currency movements.
Net sales, Adjusted EBITDA and reconciliation of GAAP net income to Adjusted EBITDA
We report Net Sales and Adjusted EBITDA by segment to understand the operating performance of each segment. This enables us to monitor changes in net sales, costs and other actionable operating metrics at the segment level. See “—General description of non-GAAP financial measures” for descriptions of EBITDA and Adjusted EBITDA.
​ ​ ​
Three Months
​ ​
Six Months
​
For the Periods Ended December 31
​ ​
2014
​ ​
2013
​ ​
Change
​ ​
2014
​ ​
2013
​ ​
Change
​
​ ​ ​
(in thousands)
​ ​
(in thousands)
​
Net Sales ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
MFAs and other
​ ​ ​ $ 87,393 ​ ​ ​ ​ $ 80,049 ​ ​ ​ ​ $ 7,344 ​ ​ ​ ​
​
9 %
​ ​ ​ ​ $ 168,175 ​ ​ ​ ​ $ 158,014 ​ ​ ​ ​ $ 10,161 ​ ​ ​ ​
​
6 %
​ ​
Nutritional specialties
​ ​ ​ ​ 20,786 ​ ​ ​ ​ ​ 16,431 ​ ​ ​ ​ ​ 4,355 ​ ​ ​ ​
​
27 %
​ ​ ​ ​ ​ 40,303 ​ ​ ​ ​ ​ 30,563 ​ ​ ​ ​ ​ 9,740 ​ ​ ​ ​
​
32 %
​ ​
Vaccines
​ ​ ​ ​ 10,606 ​ ​ ​ ​ ​ 11,486 ​ ​ ​ ​ ​ (880 ) ​ ​ ​ ​
​
(8 )%
​ ​ ​ ​ ​ 27,532 ​ ​ ​ ​ ​ 20,560 ​ ​ ​ ​ ​ 6,972 ​ ​ ​ ​
​
34 %
​ ​
Animal Health
​ ​ ​ $ 118,785 ​ ​ ​ ​ $ 107,966 ​ ​ ​ ​ ​ 10,819 ​ ​ ​ ​
​
10 %
​ ​ ​ ​ $ 236,010 ​ ​ ​ ​ $ 209,137 ​ ​ ​ ​ ​ 26,873 ​ ​ ​ ​
​
13 %
​ ​
Mineral Nutrition
​ ​ ​ ​ 58,742 ​ ​ ​ ​ ​ 50,633 ​ ​ ​ ​ ​ 8,109 ​ ​ ​ ​
​
16 %
​ ​ ​ ​ ​ 114,189 ​ ​ ​ ​ ​ 96,819 ​ ​ ​ ​ ​ 17,370 ​ ​ ​ ​
​
18 %
​ ​
Performance Products
​ ​ ​ ​ 11,161 ​ ​ ​ ​ ​ 14,143 ​ ​ ​ ​ ​ (2,982 ) ​ ​ ​ ​
​
(21 )%
​ ​ ​ ​ ​ 25,947 ​ ​ ​ ​ ​ 29,014 ​ ​ ​ ​ ​ (3,067 ) ​ ​ ​ ​
​
(11 )%
​ ​
Total
​ ​ ​ $ 188,688 ​ ​ ​ ​ $ 172,742 ​ ​ ​ ​ $ 15,946 ​ ​ ​ ​
​
9 %
​ ​ ​ ​ $ 376,146 ​ ​ ​ ​ $ 334,970 ​ ​ ​ ​ $ 41,176 ​ ​ ​ ​
​
12 %
​ ​
Adjusted EBITDA ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Animal Health
​ ​ ​ $ 28,296 ​ ​ ​ ​ $ 24,522 ​ ​ ​ ​ $ 3,774 ​ ​ ​ ​
​
15 %
​ ​ ​ ​ $ 60,750 ​ ​ ​ ​ $ 48,629 ​ ​ ​ ​ $ 12,121 ​ ​ ​ ​
​
25 %
​ ​
Mineral Nutrition
​ ​ ​ ​ 3,754 ​ ​ ​ ​ ​ 2,878 ​ ​ ​ ​ ​ 876 ​ ​ ​ ​
​
30 %
​ ​ ​ ​ ​ 7,233 ​ ​ ​ ​ ​ 5,338 ​ ​ ​ ​ ​ 1,895 ​ ​ ​ ​
​
36 %
​ ​
Performance Products
​ ​ ​ ​ 162 ​ ​ ​ ​ ​ 1,103 ​ ​ ​ ​ ​ (941 ) ​ ​ ​ ​
​
(85 )%
​ ​ ​ ​ ​ 1,198 ​ ​ ​ ​ ​ 2,199 ​ ​ ​ ​ ​ (1,001 ) ​ ​ ​ ​
​
(46 )%
​ ​
Corporate
​ ​ ​ ​ (7,184 ) ​ ​ ​ ​ ​ (6,193 ) ​ ​ ​ ​ ​ (991 ) ​ ​ ​ ​
​
*
​ ​ ​ ​ ​ (13,695 ) ​ ​ ​ ​ ​ (12,258 ) ​ ​ ​ ​ ​ (1,437 ) ​ ​ ​ ​
​
*
​ ​
Total
​ ​ ​ $ 25,028 ​ ​ ​ ​ $ 22,310 ​ ​ ​ ​ $ 2,718 ​ ​ ​ ​
​
12 %
​ ​ ​ ​ $ 55,486 ​ ​ ​ ​ $ 43,908 ​ ​ ​ ​ $ 11,578 ​ ​ ​ ​
​
26 %
​ ​
Adjusted EBITDA ratio to segment net sales
​ ​ ​ ​ ​ ​ ​ ​ ​
Animal Health
​ ​ ​ ​ 23.8 % ​ ​ ​ ​ ​ 22.7 % ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 25.7 % ​ ​ ​ ​ ​ 23.3 % ​ ​ ​ ​
Mineral Nutrition
​ ​ ​ ​ 6.4 % ​ ​ ​ ​ ​ 5.7 % ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 6.3 % ​ ​ ​ ​ ​ 5.5 % ​ ​ ​ ​
Performance Products
​ ​ ​ ​ 1.5 % ​ ​ ​ ​ ​ 7.8 % ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 4.6 % ​ ​ ​ ​ ​ 7.6 % ​ ​ ​ ​
Corporate (1)
​ ​ ​ ​ (3.8 )% ​ ​ ​ ​ ​ (3.6 )% ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ (3.6 )% ​ ​ ​ ​ ​ (3.7 )% ​ ​ ​ ​
Total (1)
​ ​ ​ ​ 13.3 % ​ ​ ​ ​ ​ 12.9 % ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 14.8 % ​ ​ ​ ​ ​ 13.1 % ​ ​ ​ ​
​
(1)
reflects ratio to total net sales
​
A reconciliation of GAAP net income to Adjusted EBITDA:
​ ​ ​
Three Months
​ ​
Six Months
​
For the Periods Ended December 31
​ ​
2014
​ ​
2013
​ ​
Change
​ ​
2014
​ ​
2013
​ ​
Change
​
​ ​ ​
(in thousands)
​ ​
(in thousands)
​
Net income
​ ​ ​ $ 15,405 ​ ​ ​ ​ $ 2,302 ​ ​ ​ ​ $ 13,103 ​ ​ ​ ​
​
569 %
​ ​ ​ ​ $ 35,886 ​ ​ ​ ​ $ 8,145 ​ ​ ​ ​ $ 27,741 ​ ​ ​ ​
​
341 %
​ ​
Interest expense, net
​ ​ ​ ​ 3,515 ​ ​ ​ ​ ​ 8,719 ​ ​ ​ ​ ​ (5,204 ) ​ ​ ​ ​
​
(60 )%
​ ​ ​ ​ ​ 7,005 ​ ​ ​ ​ ​ 17,454 ​ ​ ​ ​ ​ (10,449 ) ​ ​ ​ ​
​
(60 )%
​ ​
Provision for income taxes
​ ​ ​ ​ 1,885 ​ ​ ​ ​ ​ 4,832 ​ ​ ​ ​ ​ (2,947 ) ​ ​ ​ ​
​
(61 )%
​ ​ ​ ​ ​ 4,223 ​ ​ ​ ​ ​ 6,003 ​ ​ ​ ​ ​ (1,780 ) ​ ​ ​ ​
​
(30 )%
​ ​
Depreciation and amortization
​ ​ ​ ​ 5,241 ​ ​ ​ ​ ​ 5,292 ​ ​ ​ ​ ​ (51 ) ​ ​ ​ ​
​
(1 )%
​ ​ ​ ​ ​ 10,594 ​ ​ ​ ​ ​ 10,493 ​ ​ ​ ​ ​ 101 ​ ​ ​ ​
​
1 %
​ ​
EBITDA
​ ​ ​ ​ 26,046 ​ ​ ​ ​ ​ 21,145 ​ ​ ​ ​ ​ 4,901 ​ ​ ​ ​
​
23 %
​ ​ ​ ​ ​ 57,708 ​ ​ ​ ​ ​ 42,095 ​ ​ ​ ​ ​ 15,613 ​ ​ ​ ​
​
37 %
​ ​
Foreign currency (gains) losses, net
​ ​ ​ ​ (1,018 ) ​ ​ ​ ​ ​ 1,165 ​ ​ ​ ​ ​ (2,183 ) ​ ​ ​ ​
​
*
​ ​ ​ ​ ​ (2,222 ) ​ ​ ​ ​ ​ 1,813 ​ ​ ​ ​ ​ (4,035 ) ​ ​ ​ ​
​
*
​ ​
Adjusted EBITDA
​ ​ ​ $ 25,028 ​ ​ ​ ​ $ 22,310 ​ ​ ​ ​ $ 2,718 ​ ​ ​ ​
​
12 %
​ ​ ​ ​ $ 55,486 ​ ​ ​ ​ $ 43,908 ​ ​ ​ ​ $ 11,578 ​ ​ ​ ​
​
26 %
​ ​
​
​
Certain amounts and percentages may reflect rounding adjustments
*
Calculation not meaningful
​
Adjusted net income
We report Adjusted Net Income to portray the results of our operations prior to considering certain income statement elements. See “—General description of non-GAAP financial measures” for more information.
18
A reconciliation of GAAP net income to adjusted net income:
​ ​ ​
Three Months
​ ​
|
​ ​
Six Months
​ ​ ​
As Reported
​ ​
Adjustments
​ ​
Adjusted
​ ​
|
​ ​
As Reported
​ ​
Adjustments
​ ​
Adjusted
For the Periods Ended December 31
​ ​
2014
​ ​
2013
​ ​
2014
​ ​
2013
​ ​
2014
​ ​
2013
​ ​
|
​ ​
2014
​ ​
2013
​ ​
2014
​ ​
2013
​ ​
2014
​ ​
2013
​ ​ ​
(in thousands, exept per share amounts)
​ ​
|
​ ​
(in thousands, except per share amounts)
Selling, general and administrative expenses (1)(2)
​ ​ ​ $ 36,298 ​ ​ ​ ​ $ 34,138 ​ ​ ​ ​ $ (1,057 ) ​ ​ ​ ​ $ (1,213 ) ​ ​ ​ ​ $ 35,241 ​ ​ ​ ​ $ 32,925 ​ ​ ​
|
|
​ ​ ​ $ 71,522 ​ ​ ​ ​ $ 67,253 ​ ​ ​ ​ $ (2,126 ) ​ ​ ​ ​ $ (2,590 ) ​ ​ ​ ​ $ 69,396 ​ ​ ​ ​ $ 64,663
Operating income
​ ​ ​ ​ 19,787 ​ ​ ​ ​ ​ 17,018 ​ ​ ​ ​ ​ 1,057 ​ ​ ​ ​ ​ 1,213 ​ ​ ​ ​ ​ 20,844 ​ ​ ​ ​ ​ 18,231 ​ ​ ​
|
​ ​ ​ ​ 44,892 ​ ​ ​ ​ ​ 33,415 ​ ​ ​ ​ ​ 2,126 ​ ​ ​ ​ ​ 2,590 ​ ​ ​ ​ ​ 47,018 ​ ​ ​ ​ ​ 36,005
Foreign currency (gains) losses, net
​ ​ ​ ​ (1,018 ) ​ ​ ​ ​ ​ 1,165 ​ ​ ​ ​ ​ 1,018 ​ ​ ​ ​ ​ (1,165 ) ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​
|
​ ​ ​ ​ (2,222 ) ​ ​ ​ ​ ​ 1,813 ​ ​ ​ ​ ​ 2,222 ​ ​ ​ ​ ​ (1,813 ) ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ —
Income before income taxes
​ ​ ​ ​ 17,290 ​ ​ ​ ​ ​ 7,134 ​ ​ ​ ​ ​ 39 ​ ​ ​ ​ ​ 2,378 ​ ​ ​ ​ ​ 17,329 ​ ​ ​ ​ ​ 9,512 ​ ​ ​
|
​ ​ ​ ​ 40,109 ​ ​ ​ ​ ​ 14,148 ​ ​ ​ ​ ​ (96 ) ​ ​ ​ ​ ​ 4,403 ​ ​ ​ ​ ​ 40,013 ​ ​ ​ ​ ​ 18,551
Provision for income taxes (3)
​ ​ ​ ​ 1,885 ​ ​ ​ ​ ​ 4,832 ​ ​ ​ ​ ​ 1,335 ​ ​ ​ ​ ​ (3,580 ) ​ ​ ​ ​ ​ 3,220 ​ ​ ​ ​ ​ 1,252 ​ ​ ​
|
​ ​ ​ ​ 4,223 ​ ​ ​ ​ ​ 6,003 ​ ​ ​ ​ ​ 1,440 ​ ​ ​ ​ ​ (2,168 ) ​ ​ ​ ​ ​ 5,663 ​ ​ ​ ​ ​ 3,835
Net income
​ ​ ​ $ 15,405 ​ ​ ​ ​ $ 2,302 ​ ​ ​ ​ $ (1,296 ) ​ ​ ​ ​ $ 5,958 ​ ​ ​ ​ $ 14,109 ​ ​ ​ ​ $ 8,260 ​ ​ ​
|
​ ​ ​ $ 35,886 ​ ​ ​ ​ $ 8,145 ​ ​ ​ ​ $ (1,536 ) ​ ​ ​ ​ $ 6,571 ​ ​ ​ ​ $ 34,350 ​ ​ ​ ​ $ 14,716
Net income per share ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
|
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
basic
​ ​ ​ $ 0.40 ​ ​ ​ ​ $ 0.08 ​ ​ ​ ​ $ (0.03 ) ​ ​ ​ ​ $ 0.20 ​ ​ ​ ​ $ 0.36 ​ ​ ​ ​ $ 0.27 ​ ​ ​
|
​ ​ ​ $ 0.92 ​ ​ ​ ​ $ 0.27 ​ ​ ​ ​ $ (0.04 ) ​ ​ ​ ​ $ 0.22 ​ ​ ​ ​ $ 0.88 ​ ​ ​ ​ $ 0.48
diluted
​ ​ ​ $ 0.39 ​ ​ ​ ​ $ 0.08 ​ ​ ​ ​ $ (0.03 ) ​ ​ ​ ​ $ 0.20 ​ ​ ​ ​ $ 0.35 ​ ​ ​ ​ $ 0.27 ​ ​ ​
|
​ ​ ​ $ 0.90 ​ ​ ​ ​ $ 0.27 ​ ​ ​ ​ $ (0.04 ) ​ ​ ​ ​ $ 0.22 ​ ​ ​ ​ $ 0.87 ​ ​ ​ ​ $ 0.48
Weighted average common shares outstanding
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
|
|
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
basic
​ ​ ​ ​ 38,957 ​ ​ ​ ​ ​ 30,458 ​ ​ ​ ​ ​ 38,957 ​ ​ ​ ​ ​ 30,458 ​ ​ ​ ​ ​ 38,957 ​ ​ ​ ​ ​ 30,458 ​ ​ ​
|
​ ​ ​ ​ 38,928 ​ ​ ​ ​ ​ 30,458 ​ ​ ​ ​ ​ 38,928 ​ ​ ​ ​ ​ 30,458 ​ ​ ​ ​ ​ 38,928 ​ ​ ​ ​ ​ 30,458
diluted
​ ​ ​ ​ 39,813 ​ ​ ​ ​ ​ 30,458 ​ ​ ​ ​ ​ 39,813 ​ ​ ​ ​ ​ 30,458 ​ ​ ​ ​ ​ 39,813 ​ ​ ​ ​ ​ 30,458 ​ ​ ​
|
​ ​ ​ ​ 39,690 ​ ​ ​ ​ ​ 30,458 ​ ​ ​ ​ ​ 39,690 ​ ​ ​ ​ ​ 30,458 ​ ​ ​ ​ ​ 39,690 ​ ​ ​ ​ ​ 30,458
Ratio to net sales ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
|
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Selling, general and administrative
expenses
​ ​ ​ ​ 19.2 % ​ ​ ​ ​ ​ 19.8 % ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 18.7 % ​ ​ ​ ​ ​ 19.1 % ​ ​ ​
|
|
​ ​ ​ ​ 19.0 % ​ ​ ​ ​ ​ 20.1 % ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 18.4 % ​ ​ ​ ​ ​ 19.3 %
Operating income
​ ​ ​ ​ 10.5 % ​ ​ ​ ​ ​ 9.9 % ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 11.0 % ​ ​ ​ ​ ​ 10.6 % ​ ​ ​
|
​ ​ ​ ​ 11.9 % ​ ​ ​ ​ ​ 10.0 % ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 12.5 % ​ ​ ​ ​ ​ 10.7 %
Income before income taxes
​ ​ ​ ​ 9.2 % ​ ​ ​ ​ ​ 4.1 % ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 9.2 % ​ ​ ​ ​ ​ 5.5 % ​ ​ ​
|
​ ​ ​ ​ 10.7 % ​ ​ ​ ​ ​ 4.2 % ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 10.6 % ​ ​ ​ ​ ​ 5.5 %
Net income
​ ​ ​ ​ 8.2 % ​ ​ ​ ​ ​ 1.3 % ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 7.5 % ​ ​ ​ ​ ​ 4.8 % ​ ​ ​
|
​ ​ ​ ​ 9.5 % ​ ​ ​ ​ ​ 2.4 % ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 9.1 % ​ ​ ​ ​ ​ 4.4 %
Effective tax rate
​ ​ ​ ​ 10.9 % ​ ​ ​ ​ ​ 67.7 % ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 18.6 % ​ ​ ​ ​ ​ 13.2 % ​ ​ ​
|
​ ​ ​ ​ 10.5 % ​ ​ ​ ​ ​ 42.4 % ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 14.2 % ​ ​ ​ ​ ​ 20.7 %
​
(1)
Adjustments to selling, general and administrative expense include acquisition intangible amortization of  $1,057 and $1,186 and share based compensation of  $0 and $27 for the three months ended December 31, 2014 and 2013, respectively.
​
(2)
Adjustments to selling, general and administrative expense include acquisition intangible amortization of  $2,126 and $2,535 and share based compensation of  $0 and $55 for the six months ended December 31, 2014 and 2013, respectively.
​
(3)
We adjust the provision for income taxes to reflect cash income taxes paid in the period.
​
Comparison of three months ended December 31, 2014 and 2013
Net sales
Net sales of  $188.7 million increased $15.9 million, or 9%, for the three months ended December 31, 2014, as compared to the three months ended December 31, 2013, due to growth in Animal Health and Mineral Nutrition of  $10.8 million and $8.1 million, respectively, offset by declines in Performance Products of  $3.0 million.
Animal Health
Net sales of  $118.8 million grew $10.8 million, or 10%, primarily due to volume growth. Medicated Feed Additives (“MFAs”) and other grew $7.3 million, or 9%, primarily due to volume growth in international markets. Nutritional specialty products grew $4.4 million, or 27%, primarily due to U.S. volume growth of our products for the dairy industry and their introduction in select European countries. Vaccines declined $0.9 million, or 8%, principally from volume declines due to international product registration delays, offset in part by U.S. volume growth.
Mineral Nutrition
Net sales of  $58.7 million increased $8.1 million, or 16%. Increased volumes accounted for approximately two-thirds of the sales growth, as current market conditions improved demand for certain
19
trace mineral products. The remainder of the sales increase was due to increased average selling prices due to higher underlying raw material commodity prices.
Performance Products
Net sales of  $11.2 million decreased $3.0 million, or 21%, primarily as a result of lower volumes of copper-based products due to reduced industrial demand. Lower volumes of personal care products also contributed to the decrease. Net sales also declined due to lower average selling prices related to reduced underlying raw material commodity prices.
Gross profit
Gross profit of  $56.1 million increased $5.0 million, or 10%, to 29.7% of net sales, with a majority of the improvement coming from Animal Health. Animal Health gross profit increased $5.3 million, with approximately $4.3 million due to volume growth and favorable product mix and $1.3 million due to higher average selling prices and other items, partially offset by $0.3 million of higher product costs. Within Animal Health, MFAs and other contributed $3.3 million of the increase due to volume growth and average selling prices, partially offset by higher unit costs, nutritional specialty products contributed $2.9 million of the increase primarily due to volume growth, higher average selling prices and lower unit costs from improved operating efficiencies and vaccines gross profit decreased $0.9 million principally due to volume declines and product mix. Mineral Nutrition gross profit increased $1.0 million due to higher average selling prices and higher volumes, partially offset by higher product costs. Performance Products gross profit decreased $1.1 million due to lower average selling prices and lower volumes.
Selling, general and administrative expenses
Selling, general and administrative (“SG&A”) expenses of  $36.3 million increased $2.2 million, or 6%. Animal Health accounted for $1.4 million of the increase, driven by sales and marketing and development spending. Selling headcount and related marketing support increased to support MFA and vaccine initiatives and the expansion of our products to the dairy industry. Development spending focused on product lifecycle extensions. Corporate expenses accounted for $0.8 million of the increase due to salary and wage-related costs and professional fees, in part related to the costs of being a public company.
Adjusted EBITDA
Adjusted EBITDA of  $25.0 million increased $2.7 million, or 12%. Animal Health adjusted EBITDA increased $3.8 million, or 15%, due to sales growth and increased gross profit, partially offset by increased SG&A expenses. Mineral Nutrition increased $0.9 million, or 30%, due to higher sales volumes and improved operating margins. Performance Products decreased $0.9 million, or 85%, due to lower sales volumes. Corporate expense increased $1.0 million due to increases in salary and wage-related costs and professional fees, in part related to the costs of being a public company.
Interest expense, net
Interest expense, net, of  $3.5 million decreased $5.2 million due to the net result of issuing the Term B Loan and Revolving Credit Facility in April 2014, retiring the Mayflower Term Loan, the BFI Term Loan and the Domestic Senior Credit Facility in April 2014 and redeeming the 9.25% Senior Notes in May 2014.
Foreign currency (gains) losses, net
Foreign currency (gains) losses, net for the three months ended December 31, 2014, amounted to net gains of  $1.0 million, as compared to $1.2 million in net losses for the three months ended December 31, 2013. Foreign currency gains in the current period were primarily due to the movement of Brazil, Mexico and Belgium currencies relative to the U.S. dollar. Foreign currency gains and losses primarily arise from intercompany balances.
20
Provision for income taxes
Income taxes of  $1.9 million were recorded on consolidated pre-tax income of  $17.3 million, a 10.9% effective tax rate. The tax provision is comprised primarily of income taxes relating to profitable foreign jurisdictions. The provision for income taxes on domestic pre-tax income was substantially offset by the utilization of domestic net operating losses that previously had been offset by a valuation allowance.
Comparison of six months ended December 31, 2014 and 2013
Net sales
Net sales of  $376.1 million increased $41.2 million, or 12%, for the six months ended December 31, 2014, as compared to the six months ended December 31, 2013, due to growth in Animal Health and Mineral Nutrition of  $26.9 million and $17.4 million, respectively, offset by declines in Performance Products of  $3.1 million.
The consolidated statement of operations for the six months ended December 31, 2014 included $6.0 million of revenue and gross profit related to an existing license agreement with a global animal health company to share in the use of our proprietary vaccine delivery technology. We recognized the revenue and profit during the period because certain contractual and regulatory milestones were achieved by the licensee, and we had no performance obligations under the agreement. Excluding the $6.0 million in licensing revenue, net sales growth was $35.2 million, or 11%.
Animal Health
Net sales of  $236.0 million grew $26.9 million, or 13%, primarily due to volume growth across all product groups. Excluding the $6.0 million in revenue from the licensing agreement, net sales growth was $20.9 million, or 10%. MFAs and other grew $10.2 million, or 6%, primarily due to volume growth in international markets. Nutritional specialty products grew $9.7 million, or 32%, primarily due to U.S. volume growth of our products for the dairy industry and their introduction in select European countries. Excluding the effect of the $6.0 million in licensing revenue, vaccines grew $1.0 million, or 5%, principally from volume growth.
Mineral Nutrition
Net sales of  $114.2 million increased $17.4 million, or 18%. Increased volumes accounted for approximately two thirds of the sales growth, as current market conditions improved demand for certain trace mineral products. The remainder of the sales increase was due to increased average selling prices due to higher underlying raw material commodity prices.
Performance Products
Net sales of  $25.9 million decreased $3.1 million, or 11%, due to lower volumes of copper-based products, as well as lower average selling prices and lower volumes in personal care ingredients. Net sales also declined due to lower average selling prices related to reduced underlying raw material commodity prices.
Gross profit
Gross profit of  $116.4 million increased $15.8 million, or 16%, to 31.0% of net sales, with a majority of the improvement coming from Animal Health. Gross profit growth was $9.8 million, or 10%, excluding the effect of the $6.0 million in licensing revenue. Animal Health gross profit increased $9.0 million, excluding the effect of the licensing revenue, with approximately $9.1 million due to volume growth and favorable product mix and $1.2 million due to higher average selling prices and other items, partially offset by $1.2 million of higher product costs. Within Animal Health, MFAs and other contributed $3.5 million of the increase due to volume growth and average selling prices, partially offset by higher unit costs, nutritional specialty products contributed $5.8 million of the increase primarily due to volume growth, higher average selling prices and lower unit costs from improved operating efficiencies and excluding the gross profit from the licensing revenue for the vaccine delivery technology, vaccines gross profit decreased
21
$0.3 million principally due to product mix. Mineral Nutrition gross profit increased $2.0 million due to higher average selling prices and higher volumes, partially offset by higher product costs. Performance Products gross profit increased $1.1 million due to lower average selling prices and lower volumes, partially offset by lower product costs.
Selling, general and administrative expenses
SG&A expenses of  $71.5 million increased $4.3 million, or 6%. Animal Health accounted for $2.9 million of the increase, driven by sales and marketing and development spending. Selling headcount and related marketing support increased to support MFA and vaccine initiatives and the expansion of our products to the dairy industry. Development spending focused on product lifecycle extensions. Corporate expenses accounted for $1.3 million of the increase due to salary and wage-related costs and professional fees, in part related to the costs of being a public company.
Adjusted EBITDA
Adjusted EBITDA of  $55.5 million increased $11.6 million, or 26%. Adjusted EBITDA growth was $5.6 million, or 13%, excluding the $6.0 million in revenue from the licensing agreement. Animal Health adjusted EBITDA increased $6.1 million, or 13%, excluding the effect of the licensing revenue, due to sales growth and increased gross profit, partially offset by increased SG&A expenses. Mineral Nutrition increased $1.9 million, or 36%, due to higher sales volumes and improved operating margins. Performance Products decreased $1.0 million, or 46% due to lower sales volumes. Corporate expense increased $1.4 million due to increases in salary and wage-related costs and professional fees, in part related to the costs of being a public company.
Interest expense, net
Interest expense, net, of  $7.0 million decreased $10.4 million due to the net result of issuing the Term B Loan and Revolving Credit Facility in April 2014, retiring the Mayflower Term Loan, the BFI Term Loan and the Domestic Senior Credit Facility in April 2014 and redeeming the 9.25% Senior Notes in May 2014.
Foreign currency (gains) losses, net
Foreign currency (gains) losses, net for the six months ended December 31, 2014, amounted to net gains of  $2.2 million, as compared to $1.8 million in net losses for the six months ended December 31, 2013. Foreign currency gains in the current period were primarily due to the movement of Brazil, Israel and Belgium currencies relative to the U.S. dollar. Foreign currency gains and losses primarily arise from intercompany balances.
Provision for income taxes
Income taxes of  $4.2 million were recorded on consolidated pre-tax income of  $40.1 million, a 10.5% effective tax rate. The tax provision is comprised primarily of income taxes relating to profitable foreign jurisdictions, partially offset by a $1.2 million benefit from the recognition of certain previously unrecognized tax benefits. The provision for income taxes on domestic pre-tax income was substantially offset by the utilization of domestic net operating losses that previously had been offset by a valuation allowance.
22
Analysis of financial condition, liquidity and capital resources
Net increase (decrease) in cash and cash equivalents was:
​ ​ ​
Six Months
​
For the Period Ended December 31
​ ​
2014
​ ​
2013
​ ​
Change
​
​ ​ ​
(in thousands)
​
Cash provided by/(used in): ​ ​ ​ ​
Operating activities
​ ​ ​ $ 25,763 ​ ​ ​ ​ $ 16,396 ​ ​ ​ ​ $ 9,367 ​ ​
Investing activities
​ ​ ​ ​ (6,919 ) ​ ​ ​ ​ ​ (9,756 ) ​ ​ ​ ​ ​ 2,837 ​ ​
Financing activities
​ ​ ​ ​ (9,237 ) ​ ​ ​ ​ ​ (3,178 ) ​ ​ ​ ​ ​ (6,059 ) ​ ​
Effect of exchange-rate changes on cash and cash equivalents
​ ​ ​ ​ (739 ) ​ ​ ​ ​ ​ (357 ) ​ ​ ​ ​ ​ (382 ) ​ ​
Net increase/(decrease) in cash and cash equivalents
​ ​ ​ $ 8,868 ​ ​ ​ ​ $ 3,105 ​ ​ ​ ​ $ 5,763 ​ ​
​
Net cash provided (used) by operating activities was comprised of:
​ ​ ​
Six Months
​
For the Period Ended December 31
​ ​
2014
​ ​
2013
​ ​
Change
​
​ ​ ​
(in thousands)
​
Adjusted EBITDA
​ ​ ​ $ 55,486 ​ ​ ​ ​ $ 43,908 ​ ​ ​ ​ $ 11,578 ​ ​
Interest paid
​ ​ ​ ​ (6,565 ) ​ ​ ​ ​ ​ (16,760 ) ​ ​ ​ ​ ​ 10,195 ​ ​
Income taxes paid
​ ​ ​ ​ (5,663 ) ​ ​ ​ ​ ​ (3,835 ) ​ ​ ​ ​ ​ (1,828 ) ​ ​
Changes in operating assets and liabilities and other items
​ ​ ​ ​ (17,495 ) ​ ​ ​ ​ ​ (6,917 ) ​ ​ ​ ​ ​ (10,578 ) ​ ​
Net cash provided (used) by operating activities
​ ​ ​ $ 25,763 ​ ​ ​ ​ $ 16,396 ​ ​ ​ ​ $ 9,367 ​ ​
​
​
Certain amounts may reflect rounding adjustments.
Operating activities
For the six months ended December 31, 2014, net cash provided by operating activities was $25.8 million. Increased inventories used $9.3 million of cash due to timing of purchases and production. Accrued expenses used $7.5 million of cash, including $5.3 million paid to customers related to damages to their poultry resulting from the use of one of our products in fiscal year 2010. Annual incentive compensation payments primarily accounted for the remainder of the cash used by accrued expenses.
Investing activities
For the six months ended December 31, 2014, net cash used in investing activities was $6.9 million. Capital expenditures accounted for $7.7 million of the cash used as we continued to invest in our existing asset base and for capacity expansion and productivity improvements. We also received a $0.7 million repayment of advances made to an equity method investee.
Financing activities
For the six months ended December 31, 2014, net cash used by financing activities was $9.2 million. We paid $7.8 million in dividends to holders of our Class A and Class B common stock. In addition, we made $1.5 million in scheduled payments on our Term B loan.
Liquidity and capital resources
We believe our cash on hand, our operating cash flows and our financing arrangements, including the availability of borrowings under the Revolving Credit Facility and foreign credit lines, will be sufficient to support our future cash needs. Our operating plan projects adequate liquidity throughout the year. However, we can provide no assurance that our liquidity and capital resources will be adequate for future
23
funding requirements. We believe we will be able to comply with the terms of the covenants under the Revolving Credit Facility and foreign credit lines based on our operating plan. In the event of adverse operating results and/or violation of covenants under the facilities, there can be no assurance we would be able to obtain waivers or amendments. Other risks to our meeting future funding requirements include global economic conditions and macroeconomic, business and financial disruptions that could arise. There can be no assurance that the challenging economic environment or an economic downturn would not impact our liquidity or our ability to obtain future financing.
As of
​ ​
December 31,
2014
​ ​
June 30,
2014
​ ​
Change
​
​ ​ ​
(in thousands)
​
Cash and cash equivalents
​ ​ ​ $ 20,689 ​ ​ ​ ​ $ 11,821 ​ ​ ​ ​ $ 8,868 ​ ​
Working capital
​ ​ ​ ​ 187,504 ​ ​ ​ ​ ​ 177,999 ​ ​ ​ ​ ​ 9,505 ​ ​
Ratio of current assets to current liabilities
​ ​ ​ ​ 2.90:1 ​ ​ ​ ​ ​ 2.63:1 ​ ​ ​ ​ ​ ​ ​ ​
We define working capital as total current assets (excluding cash and cash equivalents) less total current liabilities (excluding current portion of long-term debt). We calculate the ratio of current assets to current liabilities based on this definition.
At December 31, 2014, we had no outstanding borrowings under the Revolving Credit Facility. We had outstanding letters of credit and other commitments of  $17.2 million, leaving $82.8 million available for borrowings and letters of credit. In addition, we had availability totaling $15.0 million under our Israeli loan agreements.
We intend to pay quarterly dividends of  $0.10 per share, representing $15.6 million annually, on our Class A and Class B common stock, subject to approval from the Board of Directors. We declared and paid quarterly cash dividends of  $0.10 per share, during the quarters ended September 30, 2014 and December 31, 2014, totaling $7.8 million, on our Class A common stock and Class B common stock.
On February 9, 2015, our Board of Directors declared a cash dividend of  $0.10 per share on each share of our Class A and Class B common stock outstanding on the record date of March 4, 2015, payable on March 25, 2015.
At December 31, 2014, our cash and cash equivalents included $16.0 million held by our international subsidiaries. There are no restrictions on cash distributions to PAHC from our international subsidiaries.
Contractual obligations
As of the balance sheet date, there were no material changes in payments due under contractual obligations from those disclosed in the Annual Report. See “Notes to the Consolidated Financial Statement—Subsequent Event” for additional details on the impact on future contractual obligations.
Off-balance sheet arrangements
We do not currently use off-balance sheet arrangements for the purpose of credit enhancement, hedging transactions, investment or other financial purposes.
In the ordinary course of business, we may indemnify our counterparties against certain liabilities that may arise. These indemnifications typically pertain to environmental matters. If the indemnified party were to make a successful claim pursuant to the terms of the indemnification, we would be required to reimburse the loss. These indemnifications generally are subject to certain restrictions and limitations.
General description of non-GAAP financial measures
Adjusted EBITDA
Adjusted EBITDA is an alternative view of performance used by management as our primary operating measure, and we believe that investors’ understanding of our performance is enhanced by disclosing this performance measure. We report Adjusted EBITDA to portray the results of our operations
24
prior to considering certain income statement elements. We have defined EBITDA as net income plus (i) interest expense, net, (ii) provision for income taxes or less benefit for income taxes, and (iii) depreciation and amortization. We have defined Adjusted EBITDA as EBITDA plus (a) (income) loss from, and disposal of, discontinued operations, (b) other expense or less other income, as separately reported on our consolidated statements of operations, including foreign currency gains and losses and loss on extinguishment of debt, and (c) certain items that we consider to be unusual or non-recurring. The Adjusted EBITDA measure is not, and should not be viewed as, a substitute for GAAP reported net income.
The Adjusted EBITDA measure is an important internal measurement for us. We measure our overall performance on this basis in conjunction with other performance metrics. The following are examples of how our Adjusted EBITDA measure is utilized:
•
senior management receives a monthly analysis of our operating results that is prepared on an Adjusted EBITDA basis;
​
•
our annual budgets are prepared on an Adjusted EBITDA basis; and
​
•
other goal setting and performance measurements are prepared on an Adjusted EBITDA basis.
​
Despite the importance of this measure to management in goal setting and performance measurement, Adjusted EBITDA is a non-GAAP financial measure that has no standardized meaning prescribed by GAAP and, therefore, has limits in its usefulness to investors. Because of its non-standardized definition, Adjusted EBITDA, unlike GAAP net income, may not be comparable to the calculation of similar measures of other companies. Adjusted EBITDA is presented to permit investors to more fully understand how management assesses performance.
We also recognize that, as an internal measure of performance, the Adjusted EBITDA measure has limitations, and we do not restrict our performance management process solely to this metric. A limitation of the Adjusted EBITDA measure is that it provides a view of our operations without including all events during a period, such as the depreciation of property, plant and equipment or amortization of purchased intangibles, and does not provide a comparable view of our performance to other companies.
Certain significant items
Adjusted EBITDA and Adjusted net income are calculated prior to considering certain items. We evaluate such items on an individual basis. Such evaluation considers both the quantitative and the qualitative aspect of their unusual or non-operational nature. Unusual, in this context, may represent items that are not part of our ongoing business; items that, either as a result of their nature or size, we would not expect to occur as part of our normal business on a regular basis. An example of an unusual item is the loss on extinguishment of debt incurred in fiscal year 2014. We consider foreign currency gains and losses to be non-operational because they arise principally from intercompany transactions and are largely non-cash in nature.
Adjusted Net Income
Adjusted net income is an alternative view of performance and we believe investors’ understanding of our performance is enhanced by disclosing this performance measure. We report Adjusted Net Income to portray the results of our operations prior to considering certain income statement elements. We have defined adjusted net income as net income plus (i) other expense or less other income, as separately reported on our consolidated statements of operations, including foreign currency gains and losses and loss on extinguishment of debt, (ii) amortization of acquired intangibles, (iii) stock-based compensation, (iv) certain items that we consider to be unusual or non-recurring and (v) income taxes on a cash basis. The Adjusted Net Income measure is not, and should not be viewed as, a substitute for GAAP reported net income.
Adjusted Net Income is a non-GAAP financial measure that has no standardized meaning prescribed by GAAP and, therefore, has limits in its usefulness to investors. Because of its non-standardized definition, Adjusted Net Income, unlike GAAP net income, may not be comparable to the calculation of similar measures of other companies. Adjusted Net Income is presented to permit investors to more fully understand how management assesses performance.
25
New accounting standards
For discussion of new accounting standards, see “Notes to Consolidated Financial Statements—Summary of Significant Accounting Policies and New Accounting Standards.”
Critical Accounting Policies
Critical accounting policies are those that require application of management’s most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain and may change in subsequent periods. Not all of these significant accounting policies require management to make difficult, subjective or complex judgments or estimates. However, management is required to make certain estimates and assumptions during the preparation of consolidated financial statements in accordance with accounting principles generally accepted in the United States of America. Significant estimates include depreciation and amortization periods of long-lived and intangible assets, recoverability of long-lived and intangible assets and goodwill, realizability of deferred income tax and value-added tax assets, legal and environmental matters and actuarial assumptions related to the our pension plans. These estimates and assumptions impact the reported amount of assets and liabilities and disclosures of contingent assets and liabilities as of the date of the consolidated financial statements. Estimates and assumptions are reviewed periodically and the effects of revisions are reflected in the period they are determined to be necessary. Actual results could differ from those estimates. Our significant accounting policies are described in the notes to the consolidated financial statements included in the Annual Report. As of December 31, 2014, there have been no material changes to any of the critical accounting policies contained therein.
Forward-Looking Statements.
This report contains forward-looking statements that are subject to risks and uncertainties. All statements other than statements of historical or current fact included in this report are forward-looking statements. Forward-looking statements discuss our current expectations and projections relating to our financial condition, results of operations, plans, objectives, future performance and business. You can identify forward-looking statements by the fact that they do not relate strictly to historical or current facts. These statements may include words such as “aim,” “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “outlook,” “potential,” “project,” “projection,” “plan,” “intend,” “seek,” “believe,” “may,” “could,” “would,” “will,” “should,” “can,” “can have,” “likely,” the negatives thereof and other words and terms of similar meaning in connection with any discussion of the timing or nature of future operating or financial performance or other events. For example, all statements we make relating to our estimated and projected earnings, revenues, costs, expenditures, cash flows, growth rates and financial results, our plans and objectives for future operations, growth or initiatives, strategies, or the expected outcome or impact of pending or threatened litigation are forward-looking statements. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that we expected. Examples of such risks and uncertainties include:
•
restrictions on the use of antibacterials in food-producing animals may become more prevalent;
​
•
a material portion of our sales and gross profits are generated by antibacterials and other related products;
​
•
competition in each of our markets from a number of large and small companies, some of which have greater financial, research and development (“R&D”), production and other resources than we have;
​
•
the impact of current and future laws and regulatory changes;
​
•
outbreaks of animal diseases could significantly reduce demand for our products;
​
•
perceived adverse effects on human health linked to the consumption of food derived from animals that utilize our products could cause a decline in the sales of those products;
​
•
our ability to successfully implement several of our strategic initiatives;
​
​
26
•
our business may be negatively affected by weather conditions and the availability of natural resources;
​
•
the continuing trend toward consolidation of certain customer groups as well as the emergence of large buying groups;
​
•
our ability to control costs and expenses;
​
•
any unforeseen material loss or casualty;
​
•
exposure relating to rising costs and reduced customer income;
​
•
competition deriving from advances in veterinary medical practices and animal health technologies;
​
•
unanticipated safety or efficacy concerns;
​
•
our dependence on suppliers having current regulatory approvals;
​
•
our raw materials are subject to price fluctuations and their availability can be limited;
​
•
natural and man-made disasters, including but not limited to fire, snow and ice storms, flood, hail, hurricanes and earthquakes;
​
•
terrorist attacks, particularly attacks on or within markets in which we operate;
​
•
our reliance on the continued operation of our manufacturing facilities and application of our intellectual property;
​
•
adverse U.S. and international economic market conditions, including currency fluctuations;
​
•
the risks of product liability claims, legal proceedings and general litigation expenses;
​
•
our dependence on our Israeli and Brazilian operations;
​
•
our substantial level of indebtedness and related debt-service obligations;
​
•
restrictions imposed by covenants in our debt agreements;
​
•
the risk of work stoppages; and
​
•
other factors as described in “Risk Factors” in Item 1A. of our Annual Report on Form 10-K.
​
While we believe that our assumptions are reasonable, we caution that it is very difficult to predict the impact of known factors, and it is impossible for us to anticipate all factors that could affect our actual results. Important factors that could cause actual results to differ materially from our expectations, or cautionary statements, are disclosed under “Risk Factors” in our Annual Report on Form 10-K and “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” All forward-looking statements are expressly qualified in their entirety by these cautionary statements. You should evaluate all forward-looking statements made in this report in the context of these risks and uncertainties.
We caution you that the important factors referenced above may not contain all of the factors that are important to you. In addition, we cannot assure you that we will realize the results or developments we expect or anticipate or, even if substantially realized, that they will result in the consequences we anticipate or affect us or our operations in the way we expect. The forward-looking statements included in this report are made only as of the date hereof. We undertake no obligation to publicly update or revise any forward-looking statement as a result of new information, future events or otherwise, except as otherwise required by law. If we do update one or more forward-looking statements, no inference should be made that we will make additional updates with respect to those or other forward-looking statements.
27
Item 3.   Quantitative and Qualitative Disclosures about Market Risk
In the normal course of operations, we are exposed to market risks arising from adverse changes in interest rates, foreign currency exchange rates and commodity prices. As a result, future earnings, cash flows and fair values of assets and liabilities are subject to uncertainty. We use, from time to time, foreign currency contracts as a means of hedging exposure to foreign currency risks. We also utilize, on a limited basis, certain commodity derivatives, primarily on copper used in manufacturing processes, to hedge the cost of anticipated purchase or supply requirements. We do not utilize derivative instruments for trading purposes. We do not hedge our exposure to market risks in a manner that completely eliminates the effects of changing market conditions on earnings, cash flows and fair values. We monitor the financial stability and credit standing of our major counterparties.
For financial market risks related to changes in interest rates, foreign currency exchange rates and commodity prices, reference is made to the “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Qualitative and Quantitative Disclosures about Market Risk” section in the Annual Report and to the notes to the consolidated financial statements included therein.
There were no material changes in the Company’s financial market risks from the risks disclosed in the Annual Report.
Item 4.   Controls and Procedures
Evaluation of disclosure controls and procedures
An evaluation was carried out under the supervision and with the participation of the company’s management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (the “Exchange Act”)). Based upon that evaluation as of December 31, 2014, our Chief Executive Officer and Chief Financial Officer each concluded that, as of the end of such period, our disclosure controls and procedures were not effective because of material weaknesses in our internal control over financial reporting, as described in “Controls and Procedures” in the Annual Report.
Changes in Internal Control over Financial Reporting
There have been no changes in our internal control over financial reporting during the quarter ended December 31, 2014 that materially affected or are reasonably likely to materially affect, our internal control over financial reporting. We are currently evaluating the controls and procedures we will design and put in place to address the weaknesses described in “—Evaluation of disclosure controls and procedures” and plan to implement appropriate measures as part of this effort. The measures may include additional staffing and other resources to strengthen internal controls and financial reporting.
28
PART II—OTHER INFORMATION
Item 1.
Legal Proceedings
​
Information required by this Item is incorporated herein by reference to “Notes to the Consolidated Financial Statements— Commitments and Contingencies ” in Part I, Item 1, of this Quarterly Report on Form 10-Q.
Item 1A.
Risk Factors
​
In addition to the other information set forth in this Quarterly Report on Form 10-Q, you should carefully consider the factors discussed in the “Risk Factors” section in the Annual Report, which could materially affect our business, financial condition or future results.
There were no material changes in the Company’s risk factors from the risks disclosed in the Annual Report.
Item 2.
Unregistered Sales of Equity Securities and Use of Proceeds
​
None.
Item 3.
Defaults Upon Senior Securities
​
None.
Item 4.
Mine Safety Disclosures
​
None.
Item 5.
Other Information
​
None.
Item 6.
Exhibits
​
Exhibit 31.1 Chief Executive Officer—Certification pursuant to Sarbanes-Oxley Act of 2002 Section 302
Exhibit 31.2 Chief Financial Officer—Certification pursuant to Sarbanes-Oxley Act of 2002 Section 302
Exhibit 32.1* Chief Executive Officer—Certification pursuant to Sarbanes-Oxley Act of 2002 Section 906
Exhibit 32.2* Chief Financial Officer—Certification pursuant to Sarbanes-Oxley Act of 2002 Section 906
Exhibit 101.INS** XBRL Instance Document
Exhibit 101.SCH** XBRL Taxonomy Extension Schema Document
Exhibit 101.CAL** XBRL Taxonomy Extension Calculation Linkbase Document
Exhibit 101.DEF** XBRL Taxonomy Extension Definition Linkbase Document
Exhibit 101.LAB** XBRL Taxonomy Extension Label Linkbase Document
Exhibit 101.PRE** XBRL Taxonomy Extension Presentation Linkbase Document
​
*
This certification is deemed not filed for purposes of section 18 of the Exchange Act, or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act.
​
**
Furnished with this Quarterly Report. Pursuant to Rule 406T of Regulation S-T, these interactive data files are deemed not filed or part of a registration statement or prospectus for purposes of sections 11 or 12 of the Securities Act of 1933 and are deemed not filed for purposes of section 18 of the Exchange Act.
​
​
29
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
​ ​ ​ ​ Phibro Animal Health Corporation ​
​ February 10, 2015 ​ ​ By: ​ ​
/s/ Jack C. Bendheim
​
Jack C. Bendheim
President and Chief Executive Officer
​
​ February 10, 2015 ​ ​ By: ​ ​
/s/ Richard G. Johnson
​
Richard G. Johnson
Chief Financial Officer
​
30
TABLE OF CONTENTS